表紙:抗体薬物複合体市場:適応疾患別、治療領域別、リンカー別、ペイロード別、標的抗原別、主要地域別:業界動向と世界の予測、2023年~2035年
市場調査レポート
商品コード
1319260

抗体薬物複合体市場:適応疾患別、治療領域別、リンカー別、ペイロード別、標的抗原別、主要地域別:業界動向と世界の予測、2023年~2035年

Antibody Drug Conjugate Market : Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key Geographical Regions : Industry Trends and Global Forecasts, 2023-2035

出版日: | 発行: Roots Analysis | ページ情報: 英文 716 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.28円
抗体薬物複合体市場:適応疾患別、治療領域別、リンカー別、ペイロード別、標的抗原別、主要地域別:業界動向と世界の予測、2023年~2035年
出版日: 2023年07月05日
発行: Roots Analysis
ページ情報: 英文 716 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体薬物複合体市場には、140を超える超大手、大手、中堅、中小の医薬品開発企業が存在します。現在、280以上の抗体薬物複合体が承認されているか、臨床試験で評価中である一方、250の候補が前臨床段階にあることは特筆に値します。承認されているADC治療薬はすべて、固形癌または血液癌を標的として開発されています。パイプラインにある抗体薬物複合体の大部分は、癌、特に乳癌の治療薬として開発されています。

ADC治療薬は、複数の疾患経路を同時に標的とすることで有望なアプローチを提供します。Kadcylaは、乳癌患者の治療薬としてFDAから承認された最初のHER2 ADCです。その後、第一三共-アストラゼネカのエンヘルトゥとイムノメディクスのトロデルヴィの2つのADC治療薬が、転移性乳癌の二次治療薬として承認されています。さらに、第一三共-アストラゼネカのエンヘルトゥは、2023年に非小細胞肺癌の治療薬としてEUの承認を取得する見込みです。現在、乳癌治療薬として開発中の抗体薬物複合体は30種類以上あります。WHOの統計によると、乳癌は世界で最も罹患率の高い癌で、2020年末には780万人の女性が乳癌に罹患すると推定されています。同年、新たに乳癌と診断された女性の数は230万人と報告されています。

乳癌に加えて、承認されたADCは、白血病、リンパ腫、尿路上皮癌、多発性骨髄腫、子宮頸癌、卵巣癌などを適応症としています。癌疾患の有病率の増加と、癌を標的とするADC治療薬の豊富なパイプラインが、予測期間中の抗体薬物複合体市場を牽引すると予想されます。

世界の抗体薬物複合体市場は、2023年には77億2,000万米ドル規模になると推定されます。これは、さまざまなADC治療薬の販売による収益です。癌疾患の治療に有効な治療薬に対する需要の高まりに加え、開発パイプラインの増加や有望な臨床試験結果に後押しされ、抗体薬物複合体市場は予測期間中にCAGR 9.63%で成長すると予測されています。

抗体薬物複合体は、最小限の副作用で腫瘍集団を選択的に根絶するための実行可能で強力な選択肢として浮上してきました。現在に至るまで、いくつかの臨床試験で抗体薬物複合体の有効性と治療上の優位性(従来の癌治療の選択肢を上回る)が実証されています。したがって、さまざまな癌疾患の有病率の増加は、抗体薬物複合体市場の主要促進要因の1つとなっています。

現在、70種類以上の抗体薬物複合体が、乳癌をはじめとするさまざまな癌疾患の治療薬として承認されているか、HER2を標的とした臨床試験で評価されています。ロシュのKadcylaは2013年にFDAの承認を取得した最初のHER2 ADCで、次いで第一三共/アストラゼネカのEnhertuが2019年に承認を取得しました。もう一つのHER2 ADCであるAidixiは、少なくとも2種類の全身化学療法を受けた局所進行性または転移性胃癌(胃食道接合部腺癌を含む)患者の治療薬として、中国国家医薬品監督管理局から条件付き販売承認を取得しました。本薬は、中国に本拠を置くRemeGen Biosciences社によって開発されました。セーゲンはRemeGen社から、大中華圏を除く全世界におけるAidixiの独占的開発・商業化ライセンスを取得しました。HER2 ADCの抗体薬物複合体市場は、予測期間中にCAGR 8.16%で成長すると予想されます。

当レポートでは、世界の抗体薬物複合体市場について調査し、市場の概要とともに、治療領域別、リンカー別、ペイロード別、標的抗原別動向、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

第4章 市場概要

  • 章の概要
  • 抗体薬物複合体:治療パイプライン
  • 抗体薬物複合体:治療開発者のリスト

第5章 標的の競争力分析

  • 章の概要
  • 主要なパラメータ
  • 調査手法
  • 標的の競合性分析:抗体薬物複合体の主要な標的

第6章 企業と薬剤プロファイル

  • 章の概要
  • ADC Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Byondis
  • Daiichi Sankyo
  • Genentech (Subsidiary of Roche)
  • Gilead Sciences
  • ImmunoGen
  • Pfizer
  • RemeGen
  • Seagen

第7章 臨床試験の分析

  • 章の概要
  • 範囲と調査手法
  • 抗体薬物複合体:臨床試験分析

第8章 主要なオピニオンリーダー

  • 章の概要
  • 仮定と主要なパラメータ
  • 調査手法
  • 抗体薬物複合体:主要なオピニオンリーダー

第9章 併用療法

第10章 パートナーシップとコラボレーション

第11章 資金調達と投資の分析

第12章 特許分析

第13章 学術助成金の分析

第14章 主要な商業化戦略

第15章 プロモーション分析

  • 章の概要
  • プロモーションキャンペーンに使用されるチャネル
  • 製品Webサイトの概要
  • 患者サポートサービスの概要と有益なダウンロード
  • Adcetris:プロモーション分析
  • Besponsa:プロモーション分析
  • Enhertu:プロモーション分析
  • Kadcyla:プロモーション分析
  • Mylotarg:プロモーション分析
  • Polivy:プロモーション分析
  • Trodelvy:プロモーション分析

第16章 成功プロトコルの分析

第17章 新規結合およびリンカー技術プラットフォーム

  • 章の概要
  • 抗体薬物複合体:複合化技術
  • 抗体薬物コンジュゲート:コンジュゲーション技術のリスト
  • 抗体薬物複合体:リンカーテクノロジー
  • 抗体薬物複合体:リンカーおよびリンカーペイロード技術のリスト
  • 結論

第18章 ヒトへの投与における最初の非臨床データの評価

第19章 原価分析

第20章 ケーススタディ1:抗体薬物複合体の受託製造

第21章 ケーススタディ2:抗体薬物複合体治療のためのコンパニオン診断

第22章 SWOT分析

第23章 市場予測と機会分析

  • 章の概要
  • 予測調査手法と主要な前提条件
  • 世界の抗体薬物複合体市場、2023年~2035年
  • 抗体薬物複合体市場:製品別売上予測、2023年~2035年

第24章 経営陣の洞察

  • 章の概要
  • Oxford Biotherapeutics
  • Angiex
  • Syndivia
  • BSP Pharmaceuticals
  • PolyTherics (an Abzena company)
  • CureMeta
  • CytomX Therapeutics
  • NBE-Therapeutics
  • Cerbios-Pharma
  • Eisai
  • AbTis
  • AmbrX
  • Synaffix
  • Pierre Fabre
  • Catalent Pharma Solutions
  • Lonza
  • Piramal Healthcare
  • Ajinomoto Bio-Pharma Services
  • Cardiff University
  • 匿名、事業開発担当ディレクター、主任CMO
  • 匿名、最高経営責任者、トップCMO

第25章 結論

第26章 付録1:表形式のデータ

第27章 付録2:企業および組織のリスト

図表

LIST OF TABLES

  • Table 3.1 List of Approved Monoclonal Antibody Therapies
  • Table 3.2 Characteristics of Small Molecules and Monoclonal Antibodies and Antibody Drug Conjugates
  • Table 3.3 Commonly Used Cytotoxins for Antibody Drug Conjugates
  • Table 3.4 Characteristics of First, Second and Third Generation Antibody Drug Conjugates
  • Table 4.1 Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Status of Development, Target Disease Indication(s), and Therapeutic Area(s)
  • Table 4.2 Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosing Frequency, Type of Therapy, Target Antigen and Antibody Isotype
  • Table 4.3 Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
  • Table 4.4 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, and Location of Headquarters
  • Table 5.1 Target Competitiveness Analysis: Information on Novel Pre-Clinical Stage Targets, Drug Candidates, Developer(s), Target Disease Indication(s) and Therapeutics Area(s)
  • Table 6.1 List of Companies Profiled
  • Table 6.2 ADC Therapeutics: Company Overview
  • Table 6.3 ADC Therapeutics: Antibody Drug Conjugate Pipeline
  • Table 6.4 Drug Profile: Zynlonta
  • Table 6.5 ADC Therapeutics: Recent Developments and Future Outlook
  • Table 6.6 Astellas Pharma: Company Overview
  • Table 6.7 Astellas Pharma: Antibody Drug Conjugate Pipeline
  • Table 6.8 Drug Profile: Padcev
  • Table 6.9 Astellas Pharma: Recent Developments and Future Outlook
  • Table 6.10 AstraZeneca: Company Overview
  • Table 6.11 AstraZeneca: Antibody Drug Conjugate Pipeline
  • Table 6.12 Drug Profile: Enhertu
  • Table 6.13 AstraZeneca: Recent Developments and Future Outlook
  • Table 6.14 Byondis: Company Overview
  • Table 6.15 Byondis: Antibody Drug Conjugate Pipeline
  • Table 6.16 Drug Profile: Trastuzumab Duocarmazine
  • Table 6.17 Byondis: Recent Developments and Future Outlook
  • Table 6.18 Daiichi Sankyo: Company Overview
  • Table 6.19 Daiichi Sankyo: Antibody Drug Conjugate Pipeline
  • Table 6.20 Drug Profile: Enhertu
  • Table 6.21 Daiichi Sankyo: Recent Development and Future Outlook
  • Table 6.22 Genentech: Company Overview
  • Table 6.23 Genentech: Antibody Drug Conjugate Pipeline
  • Table 6.24 Drug Profile: Kadcyla
  • Table 6.25 Drug Profile: Polivy
  • Table 6.26 Roche / Genentech: Recent Developments and Future Outlook
  • Table 6.27 Gilead Sciences: Company Overview
  • Table 6.28 Gilead Sciences: Antibody Drug Conjugate Pipeline
  • Table 6.29 Drug Profile: Trodelvy
  • Table 6.30 Gilead Sciences: Recent Developments and Future Outlook
  • Table 6.31 ImmunoGen: Company Overview
  • Table 6.32 ImmunoGen: Antibody Drug Conjugate Pipeline
  • Table 6.33 Drug Profile: Elahere
  • Table 6.34 ImmunoGen: Recent Developments and Future Outlook
  • Table 6.35 Pfizer: Company Overview
  • Table 6.36 Pfizer: Antibody Drug Conjugate Pipeline
  • Table 6.37 Drug Profile: Mylotarg
  • Table 6.38 Drug Profile: Besponsa
  • Table 6.39 Pfizer: Recent Developments and Future Outlook
  • Table 6.40 RemeGen: Company Overview
  • Table 6.41 RemeGen: Antibody Drug Conjugate Pipeline
  • Table 6.42 Drug Profile: Disitamab vedotin
  • Table 6.43 RemeGen: Recent Developments and Future Outlook
  • Table 6.44 Seagen: Company Overview
  • Table 6.45 Seagen: Antibody Drug Conjugate Pipeline
  • Table 6.46 Drug Profile: Adcetris
  • Table 6.47 Drug Profile: Padcev
  • Table 6.48 Drug Profile: Tivdak
  • Table 6.49 Seagen: Recent Developments and Future Outlook
  • Table 8.1 Antibody Drug Conjugates: List of Principal Investigators
  • Table 10.1 Antibody Drug Conjugates: List of Partnerships and Collaborations, 2014-2023
  • Table 11.1 Antibody Drug Conjugates: List of Funding and Investments, 2014-2023
  • Table 11.2 Funding and Investment Analysis: Summary of Investments
  • Table 12.1 Patent Analysis: Top CPC Sections
  • Table 12.2 Patent Analysis: Top CPC Symbols
  • Table 12.3 Patent Analysis: Top CPC Codes
  • Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 12.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
  • Table 14.1 List of Conferences Related to Approved Antibody Drug Conjugates
  • Table 14.2 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
  • Table 15.1 Promotional / Marketing Strategy: Informative Downloads
  • Table 15.2 Adcetris: Drug Overview
  • Table 15.3 Besponsa: Drug Overview
  • Table 15.4 Enhertu: Drug Overview
  • Table 15.5 Kadcyla: Drug Overview
  • Table 15.6 Mylotarg: Drug Overview
  • Table 15.7 Polivy: Drug Overview
  • Table 15.8 Trodelvy: Drug Overview
  • Table 16.1 List of Top Approved Antibody Drug Conjugates
  • Table 16.2 Adcetris (Seagen / Takeda Oncology): Success Protocol Analysis Parameters
  • Table 16.3 Besponsa (UCB / Pfizer): Success Protocol Analysis Parameters
  • Table 16.4 Elahere (ImmunoGen): Success Protocol Analysis Parameters
  • Table 16.5 Enhertu (Seagen / Takeda Oncology): Success Protocol Analysis Parameters
  • Table 16.6 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis Parameters
  • Table 16.7 Padcev (Seagen / Astellas Pharma): Success Protocol Analysis Parameters
  • Table 16.8 Polivy (Genentech): Success Protocol Analysis Parameters
  • Table 16.9 Tivdak (Seagen / Genmab): Success Protocol Analysis Parameters
  • Table 16.10 Trodelvy (Gilead Sciences): Success Protocol Analysis Parameters
  • Table 16.11 Zynlonta (ADC Therapeutics): Success Protocol Analysis Parameters
  • Table 17.1 Antibody Drug Conjugate Conjugation Technologies: Information on Generation of Technology, Type of Specificity, Type of Conjugation and Drug Antibody Ratio
  • Table 17.2 Antibody Drug Conjugate Linker and Linker-Payload Technologies: Information on Manufacturer, Linker Name and Type of Linker
  • Table 18.1 Antibody Drug Conjugates Non-Clinical Studies: Safety Packages Required
  • Table 18.2 Kadcyla: GLP Toxicology Study Results
  • Table 18.3 Antibody Drug Conjugates: Dose Limiting Toxicities in Clinical Studies
  • Table 18.4 Antibody Drug Conjugates: Relationship Between Dose-Limiting Toxicities and Antibody Drug Conjugate Warhead
  • Table 19.1 Antibody Drug Conjugates Components: Information on the Cost of Different Types of Linkers
  • Table 19.2 Antibody Drug Conjugates Component: Information on Cost by Type of Cytotoxin
  • Table 19.3 Price of Marketed Antibody Drug Conjugates
  • Table 19.4 Price of Marketed Targeted Drugs
  • Table 20.1 Antibody Drug Conjugates Contract Manufacturing Service Providers: List of Companies
  • Table 20.2 Antibody Drug Conjugates Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Payloads Manufacturing Service Providers
  • Table 20.3 Antibody Drug Conjugates Contract Manufacturing Service Providers: Information on Scale of Operation
  • Table 20.4 Antibody Drug Conjugate Contract Manufacturing Service Providers: Information on Location of Dedicated Manufacturing Facilities
  • Table 21.1 Companion Diagnostics: List of Available / Under Development Tests for Antibody Drug Conjugates
  • Table 21.2 Companion Diagnostics: Partnerships and Collaborations, 2017-2021
  • Table 21.3 Companion Diagnostics for Antibody Therapeutics: List of Available / Under Development Tests
  • Table 23.1 Antibody Drug Conjugates: List of Forecasted Therapies
  • Table 23.2 Adcetris (Seagen / Takeda Oncology): Net Present Value (USD Billion)
  • Table 23.3 Adcetris (Seagen / Takeda Oncology): Value Creation Analysis (USD Billion)
  • Table 23.4 Aidixi (RemeGen): Net Present Value (USD Billion)
  • Table 23.5 Aidixi (RemeGen): Value Creation Analysis (USD Billion)
  • Table 23.6 Besponsa (Pfizer / UCB): Net Present Value (USD Billion)
  • Table 23.7 Besponsa (Pfizer / UCB): Value Creation Analysis (USD Billion)
  • Table 23.8 Blenrep (GSK): Net Present Value (USD Billion)
  • Table 23.9 Blenrep (GSK): Value Creation Analysis (USD Billion)
  • Table 23.10 Elahere (ImmunoGen): Net Present Value (USD Billion)
  • Table 23.11 Elahere (ImmunoGen): Value Creation Analysis (USD Billion)
  • Table 23.12 Enhertu (Daiichi Sankyo / AstraZeneca): Net Present Value (USD Billion)
  • Table 23.13 Enhertu (Daiichi Sankyo / AstraZeneca): Value Creation Analysis (USD Billion)
  • Table 23.14 Kadcyla (Genentech / ImmunoGen): Net Present Value (USD Billion)
  • Table 23.15 Kadcyla (Genentech / ImmunoGen): Value Creation Analysis (USD Billion)
  • Table 23.16 Padcev (Seagen / Astellas Pharma): Net Present Value (USD Billion)
  • Table 23.17 Padcev (Seagen / Astellas Pharma): Value Creation Analysis (USD Billion)
  • Table 23.18 Polivy (Genentech): Net Present Value (USD Billion)
  • Table 23.19 Polivy (Genentech): Value Creation Analysis (USD Billion)
  • Table 23.20 Tivdak (Seagen / Genmab): Net Present Value (USD Billion)
  • Table 23.21 Tivdak (Seagen / Genmab): Value Creation Analysis (USD Billion)
  • Table 23.22 Trodelvy (Gilead Sciences): Net Present Value (USD Billion)
  • Table 23.23 Trodelvy (Gilead Sciences): Value Creation Analysis (USD Billion)
  • Table 23.24 Zynlonta (ADC Therapeutics): Net Present Value (USD Billion)
  • Table 23.25 Zynlonta (ADC Therapeutics): Value Creation Analysis (USD Billion)
  • Table 23.26 Datopotamab Deruxtecan (Daiichi Sankyo): Net Present Value (USD Billion)
  • Table 23.27 Datopotamab Deruxtecan (Daiichi Sankyo): Value Creation Analysis (USD Billion)
  • Table 23.28 Patritumab Deruxtecan (Daiichi Sankyo): Net Present Value (USD Billion)
  • Table 23.29 Patritumab Deruxtecan (Daiichi Sankyo): Value Creation Analysis (USD Billion)
  • Table 23.30 SHR-A1811 (Luzsana Biotechnology): Net Present Value (USD Billion)
  • Table 23.31 SHR-A1811 (Luzsana Biotechnology): Value Creation Analysis (USD Billion)
  • Table 23.32 SKB264 (Klus Pharma): Net Present Value (USD Billion)
  • Table 23.33 SKB264 (Klus Pharma): Value Creation Analysis (USD Billion)
  • Table 23.34 TAA013 (Tot Biopharm): Net Present Value (USD Billion)
  • Table 23.35 TAA013 (Tot Biopharm): Value Creation Analysis (USD Billion)
  • Table 23.36 Telisotuzumab Vedotin (Abbvie): Net Present Value (USD Billion)
  • Table 23.37 Telisotuzumab Vedotin (Abbvie): Value Creation Analysis (USD Billion)
  • Table 23.38 Trastuzumab Duocarmazine (Byondis): Net Present Value (USD Billion)
  • Table 23.39 Trastuzumab Duocarmazine (Byondis): Value Creation Analysis (USD Billion)
  • Table 23.40 Tusamitamab Ravtansine (Sanofi / ImmunoGen): Net Present Value (USD Billion)
  • Table 23.41 Tusamitamab Ravtansine (Sanofi / ImmunoGen): Value Creation Analysis (USD Billion)
  • Table 23.42 Upifitamab Rilsodotin (Mersana Therapeutics): Net Present Value (USD Billion)
  • Table 23.43 Upifitamab Rilsodoti (Mersana Therapeutics): Value Creation Analysis (USD Billion)
  • Table 24.1 Angiex: Key Highlights
  • Table 24.2 Syndivia: Key Highlights
  • Table 24.3 BSP Pharmaceuticals: Key Highlights
  • Table 24.4 PolyTherics: Key Highlights
  • Table 24.5 CureMeta: Key Highlights
  • Table 24.6 CytomX: Key Highlights
  • Table 24.7 NBE-Therapeutics: Key Highlights
  • Table 24.8 Cerbios-Pharma: Key Highlights
  • Table 24.9 Eisai: Key Highlights
  • Table 24.10 AbTis: Key Highlights
  • Table 24.11 AmbrX: Key Highlights
  • Table 24.12 Synaffix: Key Highlights
  • Table 24.13 Pierre Fabre: Key Highlights
  • Table 24.14 Catalent Pharma Solutions: Key Highlights
  • Table 24.15 Lonza: Key Highlights
  • Table 24.16 Piramal Healthcare: Key Highlights
  • Table 24.17 Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 24.18 Cardiff University: Key Highlights
  • Table 26.1 Antibody Drug Conjugates: Distribution by Status of Development
  • Table 26.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
  • Table 26.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
  • Table 26.4 Antibody Drug Conjugates: Distribution by Line of Treatment
  • Table 26.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
  • Table 26.6 Antibody Drug Conjugates: Distribution by Type of Therapy
  • Table 26.7 Antibody Drug Conjugates: Distribution by Target Antigen
  • Table 26.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
  • Table 26.9 Antibody Drug Conjugates: Distribution by Type of Payload / Cytotoxin / Warhead
  • Table 26.10 Antibody Drug Conjugates: Distribution by Type of Payload
  • Table 26.11 Antibody Drug Conjugates: Distribution by Linker
  • Table 26.12 Antibody Drug Conjugates: Distribution by Type of Linker
  • Table 26.13 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
  • Table 26.14 Antibody Drug Conjugates Developers: Distribution by Company Size
  • Table 26.15 Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
  • Table 26.16 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
  • Table 26.17 Most Active Players: Distribution by Number of Antibody Drug Conjugates
  • Table 26.18 ADC Therapeutics: Annual Revenues, 2021-2022 (USD Million)
  • Table 26.19 Astellas Pharma: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
  • Table 26.20 AstraZeneca: Annual Revenues, 2018-2022 (USD Billion)
  • Table 26.21 Byondis: Annual Revenues, 2019-2022 (EUR Million)
  • Table 26.22 Daiichi Sankyo: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
  • Table 26.23 Roche (Parent Company of Genentech): Annual Revenues, 2018-2022 (CHF Billion)
  • Table 26.24 Gilead Sciences: Annual Revenues, 2018-2022 (USD Billion)
  • Table 26.25 ImmunoGen: Annual Revenues, 2018-2022 (USD Million)
  • Table 26.26 Pfizer: Annual Revenues, 2018-2022 (USD Billion)
  • Table 26.27 RemGen: Annual Revenues, 2021-9M 2022 (CNY Million)
  • Table 26.28 Seagen: Annual Revenues, 2018-2022 (USD Million)
  • Table 26.29 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2023
  • Table 26.30 Clinical Trial Analysis: Distribution by Trial Status
  • Table 26.31 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Table 26.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2022
  • Table 26.33 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
  • Table 26.34 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 26.35 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Table 26.36 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 26.37 Clinical Trial Analysis: Distribution by Target Population
  • Table 26.38 Clinical Trial Analysis: Distribution by Study Design
  • Table 26.39 Most Active Industry Players: Distribution by Number of Trials
  • Table 26.40 Most Active Non-Industry Players: Distribution by Number of Trials
  • Table 26.41 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Table 26.42 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
  • Table 26.43 Antibody Drug Conjugates KOL Analysis: Distribution by Type of KOLs
  • Table 26.44 Antibody Drug Conjugates KOL Analysis: Distribution by Qualification(s)
  • Table 26.45 Antibody Drug Conjugates KOL Analysis: Distribution by Affiliated Organization
  • Table 26.46 Antibody Drug Conjugates KOL Analysis: Distribution by Type of Organization
  • Table 26.47 Antibody Drug Conjugates: Geographical Distribution of KOLs
  • Table 26.48 Antibody Drug Conjugates Most Prominent KOLs: Distribution by RA Score
  • Table 26.49 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Table 26.50 Antibody Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
  • Table 26.51 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
  • Table 26.52 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
  • Table 26.53 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
  • Table 26.54 Most Popular Antibody Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
  • Table 26.55 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
  • Table 26.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
  • Table 26.57 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 26.58 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2023
  • Table 26.59 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Table 26.60 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 26.61 Most Active Players: Distribution by Number for Partnerships
  • Table 26.62 Partnerships and Collaborations: International and Local Agreements
  • Table 26.63 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Table 26.64 Funding and Investment Analysis: Cumulative Distribution of Instances, Pre-2016-2023
  • Table 26.65 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2016-2023 (USD Million)
  • Table 26.66 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Table 26.67 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 26.68 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
  • Table 26.69 Funding and Investment Analysis: Distribution of Instances by Type of Investor
  • Table 26.70 Funding and Investment Analysis: Distribution of Funding Instances by Region
  • Table 26.71 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
  • Table 26.72 Most Active Players: Distribution by Number of Funding Instances
  • Table 26.73 Most Active Players: Distribution by Amount Invested (USD Million)
  • Table 26.74 Key Investors: Distribution by Number of Instances
  • Table 26.75 Patent Analysis: Distribution by Type of Patent
  • Table 26.76 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2023
  • Table 26.77 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre 2018 -2022
  • Table 26.78 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
  • Table 26.79 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
  • Table 26.80 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
  • Table 26.81 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
  • Table 26.82 Leading Industry Players: Distribution by Number of Patents
  • Table 26.83 Leading Non-Industry Players: Distribution by Number of Patents
  • Table 26.84 Leading Individual Assignees: Distribution by Number of Patents
  • Table 26.85 Patent Analysis: Distribution by Patent Age
  • Table 26.86 Grants Analysis: Cumulative Distribution by Year of Grant, 2016- 2023
  • Table 26.87 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2016- 2023
  • Table 26.88 Grants Analysis: Distribution by Funding Institute Center
  • Table 26.89 Grants Analysis: Distribution by Support Period
  • Table 26.90 Grants Analysis: Distribution by Type of Grant Applications
  • Table 26.91 Grants Analysis: Distribution by Purpose of Grant Award
  • Table 26.92 Grants Analysis: Distribution by Activity Code
  • Table 26.93 Grants Analysis: Distribution by Study Section Involved
  • Table 26.94 Popular NIH Departments: Distribution by Number of Grants
  • Table 26.95 Prominent Program Officers: Distribution by Number of Grants
  • Table 26.96 Popular Recipient Organizations: Distribution by Number of Grants
  • Table 26.97 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Table 26.98 Grants Analysis: Distribution by Region of Recipient Organization
  • Table 26.99 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Scale of Operation
  • Table 26.100 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
  • Table 26.101 Companion Diagnostics for Antibody Therapeutics: Distribution by Target Antigen
  • Table 26.102 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
  • Table 26.103 Companion Diagnostics for Antibody Therapeutics: Distribution by Key Players
  • Table 26.104 Global Antibody Drug Conjugates Market, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.105 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
  • Table 26.106 Antibody Drug Conjugates Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.107 Antibody Drug Conjugates Market for B-cell Lymphoma, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.108 Antibody Drug Conjugates Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.109 Antibody Drug Conjugates Market for Multiplr Myeloma, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.110 Antibody Drug Conjugates Market for Renal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.111 Antibody Drug Conjugates Market for Gastric Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.112 Antibody Drug Conjugates Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.113 Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.114 Antibody Drug Conjugates Market for Other Target Disease Indication, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.115 Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Table 26.116 Antibody Drug Conjugates Market for Solid Tumors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.117 Antibody Drug Conjugates Market for Hematological Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.118 Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Linker (USD Billion)
  • Table 26.119 Antibody Drug Conjugates Market for Valine-Citrulline Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.120 Antibody Drug Conjugates Market for Tetrapeptide-based Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.121 Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.122 Antibody Drug Conjugates Market for Maleimide Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.123 Antibody Drug Conjugates Market for Maleimidocaproyl Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.124 Antibody Drug Conjugates Market for Valine-alanine Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.125 Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.126 Antibody Drug Conjugates Market for Other Linkers, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.127 Global Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Payload (USD Billion)
  • Table 26.128 Antibody Drug Conjugates Market for Monomethyl auristatin F (MMAF) Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.129 Antibody Drug Conjugates Market for DM1 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.130 Antibody Drug Conjugates Market for SN-38 / Irinotecan Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.131 Antibody Drug Conjugates Market for Monomethyl auristatin E (MMAE) Payload, Conservative, Base and Optimistic Scenarios, 2023-2035
  • Table 26.132 Antibody Drug Conjugates Market for Duocarmycin Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.133 Antibody Drug Conjugates Market for SG3199 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.134 Antibody Drug Conjugates Market for Ozogamicin Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.135 Antibody Drug Conjugates Market for DM4 Payload, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.136 Antibody Drug Conjugates Market for Other Payloads, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.137 Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Target Antigen (USD Billion)
  • Table 26.138 Antibody Drug Conjugates Market for HER-2 (ERBB2), Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.139 Antibody Drug Conjugates Market for CD79b, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.140 Antibody Drug Conjugates Market for TROP-2, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.141 Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.142 Antibody Drug Conjugates Market for CD19, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.143 Antibody Drug Conjugates Market for Nectin 4, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.144 Antibody Drug Conjugates Market for Tissue Factor, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.145 Antibody Drug Conjugates Market for CD22, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.146 Antibody Drug Conjugates Market for CD30, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.147 Antibody Drug Conjugates Market for CEACAM5, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.148 Antibody Drug Conjugates Market for Other Target Antigens, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.149 Global Antibody Drug Conjugates Market, 2023 and 2035: Distribution by Key Geographical Regions (USD Billion)
  • Table 26.150 Antibody Drug Conjugates Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.151 Antibody Drug Conjugates Market in US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.152 Antibody Drug Conjugates Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.153 Antibody Drug Conjugates Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.154 Antibody Drug Conjugates Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.155 Antibody Drug Conjugates Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.156 Antibody Drug Conjugates Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.157 Antibody Drug Conjugates Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.158 Antibody Drug Conjugates Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.159 Antibody Drug Conjugates Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.160 Antibody Drug Conjugates Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.161 Antibody Drug Conjugates Market in Australia,, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.162 Antibody Drug Conjugates Market in Japan,, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.163 Adcetris: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.164 Aidixi: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.165 Besponsa: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.166 Blenrep: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.167 Elahere: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.168 Enhertu: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.169 Kadcyla: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.170 Padcev: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.171 Polivy: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.172 Tivdak: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.173 Trodelvy: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.174 Zynlonta: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.175 Datopotamab Deruxtecan: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
  • Table 26.176 Patritumab Deruxtecan: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
  • Table 26.177 SHR-A1811: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
  • Table 26.178 SKB264: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
  • Table 26.179 TAA013: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Billion)
  • Table 26.180 Telisotuzumab Vedotin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2027-2035 (USD Billion)
  • Table 26.181 Trastuzumab Duocarmazine: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
  • Table 26.182 Tusamitamab Ravtansine: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)
  • Table 26.183 Upifitamab Rilsodotin: Sales Forecast, Conservative, Base and Optimistic Scenarios, 2026-2035 (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Market Overview
  • Figure 2.2 Executive Summary: Clinical Trial Analysis
  • Figure 2.3 Executive Summary: Partnerships and Collaborations
  • Figure 2.4 Executive Summary: Funding and Investment Analysis
  • Figure 2.5 Executive Summary: Patent Analysis
  • Figure 2.6 Executive Summary: Academic Grants Analysis
  • Figure 2.7 Executive Summary: Market Sizing and Opportunity Analysis
  • Figure 3.1 Pillars of Cancer Therapy
  • Figure 3.2 Antibody Drug Conjugates: Development History
  • Figure 3.3 Comparative Analysis of Pharmacokinetic Properties of Antibody Drug Conjugates: Dosage Regimen, Cmax and T1/2
  • Figure 3.4 Components of Antibody Drug Conjugates
  • Figure 4.1 Antibody Drug Conjugates: Distribution by Status of Development
  • Figure 4.2 Antibody Drug Conjugates: Distribution by Target Disease Indication
  • Figure 4.3 Antibody Drug Conjugates: Distribution by Therapeutic Area
  • Figure 4.4 Antibody Drug Conjugates: Distribution by Line of Treatment
  • Figure 4.5 Antibody Drug Conjugates: Distribution by Dosing Frequency
  • Figure 4.6 Antibody Drug Conjugates: Distribution by Type of Therapy
  • Figure 4.7 Antibody Drug Conjugates: Distribution by Target Antigen
  • Figure 4.8 Antibody Drug Conjugates: Distribution by Antibody Isotype
  • Figure 4.9 Antibody Drug Conjugates: Distribution by Payload / Cytotoxin / Warhead
  • Figure 4.10 Antibody Drug Conjugates: Distribution by Type of Payload
  • Figure 4.11 Antibody Drug Conjugates: Distribution by Linker
  • Figure 4.12 Antibody Drug Conjugates: Distribution by Type of Linker
  • Figure 4.13 Antibody Drug Conjugate Developers: Distribution by Year of Establishment
  • Figure 4.14 Antibody Drug Conjugate Developers: Distribution by Company Size
  • Figure 4.15 Antibody Drug Conjugate Developers: Distribution by Location of Headquarters
  • Figure 4.16 Antibody Drug Conjugate Developers: Distribution by Company Size and Location of Headquarters
  • Figure 4.17 Most Active Players: Distribution by Number of Antibody Drug Conjugates
  • Figure 5.1 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Approved / Marketed Targets
  • Figure 5.2 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase III Targets
  • Figure 5.3 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase II Targets
  • Figure 5.4 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Phase I Targets
  • Figure 5.4 Antibody Drug Conjugates: Three-Dimensional Bubble Analysis for Pre-Clinical Stage Targets
  • Figure 5.5 Antibody Drug Conjugates: Six-Dimensional Spider Web Analysis
  • Figure 6.1 ADC Therapeutics: Annual Revenues, 2021-2022 (USD Million)
  • Figure 6.2 Astellas Pharma: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
  • Figure 6.3 AstraZeneca: Annual Revenues, 2018-2022 (USD Billion)
  • Figure 6.4 Byondis: Annual Revenues, 2019-2022 (EUR Million)
  • Figure 6.5 Daiichi Sankyo: Annual Revenues, FY 2018-FY 2022 (JPY Billion)
  • Figure 6.6 Roche (Parent Company of Genentech): Annual Revenues, 2018-2022 (CHF Billion)
  • Figure 6.7 Gilead Sciences: Annual Revenues, 2018-2022 (USD Billion)
  • Figure 6.8 ImmunoGen: Annual Revenues, 2018-2022 (USD Million)
  • Figure 6.9 Pfizer: Annual Revenues, 2018-2022 (USD Billion)
  • Figure 6.10 RemeGen: Annual Revenues, 2021-9M 2022 (CNY Million)
  • Figure 6.11 Seagen: Annual Revenues, 2018-2022 (USD Million)
  • Figure 7.1 Clinical Trial Analysis: Scope and Methodology
  • Figure 7.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2016-2023
  • Figure 7.3 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 7.4 Clinical Trial Analysis: Distribution by Trial Status and Patients Enrolled
  • Figure 7.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2016-2022
  • Figure 7.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled, 2016-2022
  • Figure 7.7 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 7.8 Clinical Trial Analysis: Distribution by Trial Phase and Patients Enrolled
  • Figure 7.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 7.10 Clinical Trial Analysis: Distribution by Target Population
  • Figure 7.11 Clinical Trial Analysis: Distribution by Study Design
  • Figure 7.12 Most Active Industry Players: Distribution by Number of Trials
  • Figure 7.13 Most Active Non-Industry Players: Distribution by Number of Trials
  • Figure 7.14 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
  • Figure 8.1 Antibody Drug Conjugates KOL Analysis: Distribution by Type of KOLs
  • Figure 8.2 Antibody Drug Conjugates KOL Analysis: Distribution by Qualification
  • Figure 8.3 Antibody Drug Conjugates KOL Analysis: Distribution by Affiliated Organization
  • Figure 8.4 Antibody Drug Conjugates KOL Analysis: Distribution by Type of Organization
  • Figure 8.5 Antibody Drug Conjugates: Geographical Distribution of KOLs
  • Figure 8.6 Most Prominent Principal Investigators: Analysis by KOL Activeness, Expertise and Strength
  • Figure 8.7 Most Prominent Study Directors and Study Chairs: Analysis by KOL Activeness, Expertise and Strength
  • Figure 8.8 Antibody Drug Conjugates Most Prominent KOLs: Distribution by RA Score
  • Figure 8.9 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Figure 8.10 Antibody Drug Conjugates Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
  • Figure 9.1 Antibody Drug Conjugates Clinical Studies: Distribution by Trial Registration Year and Type of Therapy
  • Figure 9.2 Antibody Drug Conjugate-based Combination Therapies: Distribution by Phase of Development
  • Figure 9.3 Antibody Drug Conjugate-based Combination Therapies: Distribution by Trial Status
  • Figure 9.4 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication
  • Figure 9.5 Most Popular Antibody Drug Conjugates Used in Combination Therapies: Distribution by Number of Trials
  • Figure 9.6 Most Popular Drug Classes Used in Antibody Drug Conjugate-based Combination Therapies: Distribution by Number of Trials
  • Figure 9.7 Antibody Drug Conjugate-based Combination Therapies: Distribution by Target Disease Indication and Drug Class
  • Figure 9.8 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Blood Cancer
  • Figure 9.9 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Breast Cancer
  • Figure 9.10 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Renal Cancer
  • Figure 9.11 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Lung Cancer
  • Figure 9.12 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Ovarian Cancer
  • Figure 9.13 Antibody Drug Conjugate-Based Combination Therapies: Benchmarking of Popular Drug Classes for Gastric Cancer
  • Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2023
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2023
  • Figure 10.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 10.6 Most Active Players: Distribution by Number for Partnerships
  • Figure 10.7 Partnerships and Collaborations: International and Local Agreements
  • Figure 10.8 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 11.1 Funding and Investment Analysis: Cumulative Distribution of Instances, Pre-2016-2023
  • Figure 11.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2016-2023 (USD Million)
  • Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
  • Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 11.5 Funding and Investments: Distribution of Amount Invested by Year and Type of Funding
  • Figure 11.6 Funding and Investment Analysis: Distribution of Instances by Type of Investor
  • Figure 11.7 Funding and Investment Analysis: Distribution of Amount Invested by Region (USD Million)
  • Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Country (USD Million)
  • Figure 11.10 Most Active Players: Distribution by Number of Funding Instances
  • Figure 11.11 Most Active Players: Distribution by Amount Invested (USD Million)
  • Figure 11.12 Key Investors: Distribution by Number of Instances
  • Figure 12.1 Patent Analysis: Distribution by Type of Patent
  • Figure 12.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2019-2023
  • Figure 12.3 Patent Analysis: Cumulative Distribution by Patent Application Year, Pre 2018 -2022
  • Figure 12.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2019-2023
  • Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region-wise)
  • Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country-wise)
  • Figure 12.7 Patent Analysis: Distribution by CPC Symbols
  • Figure 12.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
  • Figure 12.9 Leading Industry Players: Distribution by Number of Patents
  • Figure 12.10 Leading Non-Industry Players: Distribution by Number of Patents
  • Figure 12.11 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 12.12 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
  • Figure 12.13 Patent Analysis: Distribution by Patent Age
  • Figure 12.14 Antibody Drug Conjugates: Patent Valuation
  • Figure 13.1 Grants Analysis: Cumulative Distribution by Year of Grant, 2016- 2023
  • Figure 13.2 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), 2016- 2023
  • Figure 13.3 Grants Analysis: Distribution by Funding Institute Center
  • Figure 13.4 Grants Analysis: Distribution by Support Period
  • Figure 13.5 Grants Analysis: Distribution by Type of Grant Application
  • Figure 13.6 Grants Analysis: Distribution by Purpose of Grant Award
  • Figure 13.7 Grants Analysis: Distribution by Activity Code
  • Figure 13.8 Grants Analysis: Distribution by Study Section Involved
  • Figure 13.9 Popular NIH Departments: Distribution by Number of Grants
  • Figure 13.10 Prominent Program Officers: Distribution by Number of Grants
  • Figure 13.11 Popular Recipient Organizations: Distribution by Number of Grants
  • Figure 13.12 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
  • Figure 13.13 Grants Analysis: Distribution by Region of Recipient Organization
  • Figure 14.1 Successful Drug Launch Strategy: ROOTS Framework
  • Figure 14.2 Successful Drug Launch Strategy: Product Differentiation
  • Figure 14.3 Common Commercialization Strategies Adopted Based on Development Stage of Product
  • Figure 14.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Developing Antibody Drug Conjugates
  • Figure 14.5 Antibody Drug Conjugates Approval in Multiple Geographies: Historical Timeline
  • Figure 14.6 Approved Antibody Drug Conjugates: Snapshot of Promotional Activities on Product Website
  • Figure 15.1 Channels Used for Promotional Campaigns
  • Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
  • Figure 15.3 Product Website Analysis: Adcetris, Messages for Healthcare Professionals
  • Figure 15.4 Product Website Analysis: Adcetris, Messages for Patients
  • Figure 15.5 Product Website Analysis: Adcetris, Patient Support Program
  • Figure 15.6 Product Website Analysis: Besponsa, Messages for Healthcare Professionals
  • Figure 15.7 Product Website Analysis: Besponsa, Messages for Patients
  • Figure 15.8 Product Website Analysis: Besponsa, Patient Support Program
  • Figure 15.9 Product Website Analysis: Enhertu, Messages for Healthcare Professionals
  • Figure 15.10 Product Website Analysis: Enhertu, Messages for Patients
  • Figure 15.11 Product Website Analysis: Enhertu, Patient Support Program
  • Figure 15.12 Product Website Analysis: Kadcyla, Messages for Healthcare Professionals
  • Figure 15.13 Product Website Analysis: Kadcyla, Messages for Patients
  • Figure 15.14 Product Website Analysis: Kadacyla, Patient Support Program
  • Figure 15.15 Product Website Analysis: Mylotarg, Messages for Healthcare Professionals
  • Figure 15.16 Product Website Analysis: Mylotarg, Messages for Patients
  • Figure 15.17 Product Website Analysis: Mylotarg, Patient Support Program
  • Figure 15.18 Product Website Analysis: Pfizer Oncology Together Program
  • Figure 15.19 Product Website Analysis: Polivy, Messages for Healthcare Professionals
  • Figure 15.20 Product Website Analysis: Polivy, Messages for Patients
  • Figure 15.21 Product Website Analysis: Polivy, Patient Support Program
  • Figure 15.22 Product Website Analysis: Trodelvy, Messages for Healthcare Professionals
  • Figure 15.23 Product Website Analysis: Messages for Patients
  • Figure 15.24 Product Website Analysis: Trodelvy, Patient Support Program
  • Figure 16.1 Adcetris (Seagen / Takeda Oncology): Approval Timeline
  • Figure 16.2 Adcetris (Seagen / Takeda Oncology): Success Protocol Analysis
  • Figure 16.3 Besponsa (UCB / Pfizer): Approval Timeline
  • Figure 16.4 Besponsa (UCB / Pfizer): Success Protocol Analysis
  • Figure 16.5 Elahere (ImmunoGen): Approval Timeline
  • Figure 16.6 Elahere (ImmunoGen): Success Protocol Analysis
  • Figure 16.7 Enhertu (Daiichi Sankyo / AstraZeneca): Approval Timeline
  • Figure 16.8 Enhertu (Daiichi Sankyo / AstraZeneca): Success Protocol Analysis
  • Figure 16.9 Kadcyla (Genentech / ImmunoGen): Approval Timeline
  • Figure 16.10 Kadcyla (Genentech / ImmunoGen): Success Protocol Analysis
  • Figure 16.11 Padcev (Seagen / Astellas Pharma): Approval Timeline
  • Figure 16.12 Padcev (Seagen / Astellas Pharma): Success Protocol Analysis
  • Figure 16.13 Polivy (Genentech): Approval Timeline
  • Figure 16.14 Polivy (Genentech): Success Protocol Analysis
  • Figure 16.15 Tivdak (Seagen / Genmab): Approval Timeline
  • Figure 16.16 Tivdak (Seagen / Genmab): Success Protocol Analysis
  • Figure 16.17 Trodelvy (Gilead Sciences): Approval Timeline
  • Figure 16.18 Trodelvy (Gilead Sciences): Success Protocol Analysis
  • Figure 16.19 Zynlonta (ADC Therapeutics): Approval Timeline
  • Figure 16.20 Zynlonta (ADC Therapeutics): Success Protocol Analysis
  • Figure 16.21 Success Protocol Analysis: Leading Parameters
  • Figure 18.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
  • Figure 18.2 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and Highest Non-Severely Toxic Dose (HNSTD)
  • Figure 19.1 Antibody Drug Conjugates: Key Manufacturing Steps
  • Figure 19.2 Antibody Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing
  • Figure 19.3 Antibody Drug Conjugates: Distribution by Cost involved in Clinical Stage Manufacturing (With Licensing Fees)
  • Figure 19.4 Antibody Drug Conjugates: Pricing Model Based on Patient Segment
  • Figure 20.1 Antibody Drug Conjugates: Manufacturing Steps
  • Figure 20.2 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Scale of Operation
  • Figure 20.3 Antibody Drug Conjugate Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
  • Figure 21.1 Advantages of Companion Diagnostics
  • Figure 21.2 Failure Rate: Distribution by Type of Drug Class
  • Figure 21.3 Companion Diagnostics: Primary Developmental Challenges
  • Figure 21.4 Companion Diagnostics for Antibody Therapeutics: Distribution by Target Antigen
  • Figure 21.5 Companion Diagnostics for Antibody Therapeutics: Distribution by Type of Cancer
  • Figure 21.6 Companion Diagnostics for Antibody Therapeutics: Distribution by Key Players
  • Figure 22.1 Antibody Drug Conjugates: SWOT Analysis
  • Figure 22.2 Antibody Drug Conjugates SWOT Analysis: Strengths
  • Figure 22.3 Antibody Drug Conjugates SWOT Analysis: Weaknesses
  • Figure 22.4 Antibody Drug Conjugates SWOT Analysis: Opportunities
  • Figure 22.5 Antibody Drug Conjugates SWOT Analysis: Threats
  • Figure 23.1 Global Antibody Drug Conjugates Market, 2023-2035 (USD Billion)
  • Figure 23.2 Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035 (USD Billion)
  • Figure 23.3 Antibody Drug Conjugates Market for Breast Cancer, 2023-2035 (USD Billion)
  • Figure 23.4 Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035 (USD Billion)
  • Figure 23.5 Antibody Drug Conjugates Market for Lung Cancer, 2023-2035 (USD Billion)
  • Figure 23.6 Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035 (USD Billion)
  • Figure 23.7 Antibody Drug Conjugates Market for Renal Cancer, 2023-2035 (USD Billion)
  • Figure 23.8 Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035 (USD Billion)
  • Figure 23.9 Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035 (USD Billion)
  • Figure 23.10 Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035 (USD Billion)
  • Figure 23.11 Antibody Drug Conjugates Market for Other Target Disease Indications, 2023-2035 (USD Billion)
  • Figure 23.12 Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035 (USD Billion)
  • Figure 23.13 Antibody Drug Conjugates Market for Solid Tumors, 2023-2035 (USD Billion)
  • Figure 23.14 Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035 (USD Billion)
  • Figure 23.15 Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035 (USD Billion)
  • Figure 23.16 Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035 (USD Billion)
  • Figure 23.17 Antibody Drug Conjugates Market for Tetrapeptide-based Linker, 2023-2035 (USD Billion)
  • Figure 23.18 Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035 (USD Billion)
  • Figure 23.19 Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035 (USD Billion)
  • Figure 23.20 Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035 (USD Billion)
  • Figure 23.21 Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035 (USD Billion)
  • Figure 23.22 Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035 (USD Billion)
  • Figure 23.23 Antibody Drug Conjugates Market for Other Linkers, 2023-2035 (USD Billion)
  • Figure 23.24 Antibody Drug Conjugates Market: Distribution by Payload, 2023 and 2035 (USD Billion)
  • Figure 23.25 Antibody Drug Conjugates Market for Monomethyl auristatin F (MMAF) Payload, 2023-2035 (USD Billion)
  • Figure 23.26 Antibody Drug Conjugates Market for DM1 Payload, 2023-2035 (USD Billion)
  • Figure 23.27 Antibody Drug Conjugates Market for SN-38 / Irinotecan Payload, 2023-2035 (USD Billion)
  • Figure 23.28 Antibody Drug Conjugates Market for Monomethyl auristatin E (MMAE) Payload, 2023-2035
  • Figure 23.29 Antibody Drug Conjugates Market for Duocarmycin Payload, 2023-2035 (USD Billion)
  • Figure 23.30 Antibody Drug Conjugates Market for SG3199 Payload, 2023-2035 (USD Billion)
  • Figure 23.31 Antibody Drug Conjugates Market for Ozogamicin Payload, 2023-2035 (USD Billion)
  • Figure 23.32 Antibody Drug Conjugates Market for DM4 Payload, 2023-2035 (USD Billion)
  • Figure 23.33 Antibody Drug Conjugates Market for Other Payloads, 2023-2035 (USD Billion)
  • Figure 23.34 Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035 (USD Billion)
  • Figure 23.35 Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035 (USD Billion)
  • Figure 23.36 Antibody Drug Conjugates Market for CD79b, 2023-2035 (USD Billion)
  • Figure 23.37 Antibody Drug Conjugates Market for TROP-2, 2023-2035 (USD Billion)
  • Figure 23.38 Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035 (USD Billion)
  • Figure 23.39 Antibody Drug Conjugates Market for CD19, 2023-2035 (USD Billion)
  • Figure 23.40 Antibody Drug Conjugates Market for Nectin 4, 2023-2035 (USD Billion)
  • Figure 23.41 Antibody Drug Conjugates Market for Tissue Factor, 2023-2035 (USD Billion)
  • Figure 23.42 Antibody Drug Conjugates Market for CD22, 2023-2035 (USD Billion)
  • Figure 23.43 Antibody Drug Conjugates Market for CD30, 2023-2035 (USD Billion)
  • Figure 23.44 Antibody Drug Conjugates Market for CEACAM5, 2023-2035 (USD Billion)
  • Figure 23.45 Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035 (USD Billion)
  • Figure 23.46 Antibody Drug Conjugates Market: Distribution by Key Geographical Regions, 2021 and 2030 (USD Billion)
  • Figure 23.47 Antibody Drug Conjugates Market in North America, 2023-2035 (USD Billion)
  • Figure 23.48 Antibody Drug Conjugates Market in US, 2023-2035 (USD Billion)
  • Figure 23.49 Antibody Drug Conjugates Market in Canada, 2023-2035 (USD Billion)
  • Figure 23.50 Antibody Drug Conjugates Market in Europe, 2023-2035 (USD Billion)
  • Figure 23.51 Antibody Drug Conjugates Market in Germany, 2023-2035 (USD Billion)
  • Figure 23.52 Antibody Drug Conjugates Market in UK, 2023-2035 (USD Billion)
  • Figure 23.53 Antibody Drug Conjugates Market in France, 2023-2035 (USD Billion)
  • Figure 23.54 Antibody Drug Conjugates Market in Italy, 2023-2035 (USD Billion)
  • Figure 23.55 Antibody Drug Conjugates Market in Spain, 2023-2035 (USD Billion)
  • Figure 23.56 Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035 (USD Billion)
  • Figure 23.57 Antibody Drug Conjugates Market in China, 2023-2035 (USD Billion)
  • Figure 23.58 Antibody Drug Conjugates Market in Australia, 2023-2035 (USD Billion)
  • Figure 23.59 Antibody Drug Conjugates Market in Japan, 2023-2035 (USD Billion)
  • Figure 23.60 Adcetris: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.61 Aidixi: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.62 Besponsa: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.63 Blenrep: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.64 Elahere: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.65 Enhertu: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.66 Kadcyla: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.67 Padcev: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.68 Polivy: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.69 Tivdak: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.70 Trodelvy: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.71 Zynlonta: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.72 Datopotamab Deruxtecan: Sales Forecast, 2028-2035 (USD Billion)
  • Figure 23.73 Patritumab Deruxtecan: Sales Forecast, 2028-2035 (USD Billion)
  • Figure 23.74 SHR-A1811: Sales Forecast, 2026-2035 (USD Billion)
  • Figure 23.75 SKB264: Sales Forecast, 2026-2035 (USD Billion)
  • Figure 23.76 TAA013: Sales Forecast, 2024-2035 (USD Billion)
  • Figure 23.77 Telisotuzumab Vedotin: Sales Forecast, 2027-2035 (USD Billion)
  • Figure 23.78 Trastuzumab Duocarmazine: Sales Forecast, 2023-2035 (USD Billion)
  • Figure 23.79 Tusamitamab Ravtansine: Sales Forecast, 2026-2035 (USD Billion)
  • Figure 23.80 Upifitamab Rilsodotin: Sales Forecast, 2026-2035 (USD Billion)
  • Figure 25.1 Concluding Remarks: Market Overview
  • Figure 25.2 Concluding Remarks: Clinical Trials Landscape
  • Figure 25.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 25.4 Concluding Remarks: Funding and Investment Analysis
  • Figure 25.5 Concluding Remarks: Patent Analysis
  • Figure 25.6 Concluding Remarks: Academic Grants Analysis
  • Figure 25.7 Concluding Remarks: Market Sizing and Opportunity Analysis
目次
Product Code: RA100442

INTRODUCTION

The global antibody drug conjugate market is estimated to be worth USD 7.72 billion in 2023 and expected to grow at compounded annual growth rate (CAGR) of 9.63% during the forecast period.

Antibody drug conjugates are engineered therapeutics comprised of monoclonal antibodies attached to potent cytotoxic payloads through chemical linkers. Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates (ADCs) to be recognized as potent therapies targeting a wide range of indications, including solid tumors and hematological malignancies.

14 antibody-drug conjugates, till date, have been approved by the USFDA for therapeutic use; these are ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), polatuzumab vedotin-piiq (Polivy), enfortumab vedotin (Padcev), sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu), belantamab mafodotin-blmf (Blenrep), mirvetuximab soravtansine (Elahere), tisotumab vedotin (Tivdak), cetuximab sarotalocan (Akalux), disitamab vedotin (Aidixi) and loncastuximab tesirine-lpyl (Zynlonta).

The success of ADC therapeutics can be attributed to their high tumor selectivity and cell-killing potential of these antibodies, while limiting off target toxicities. Ongoing research in this direction is driven by encouraging results achieved in past clinical trials, which were mostly focused on various solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the antibody drug conjugate market is likely to witness significant growth during the forecast period.

SCOPE OF THE REPORT

The Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts market report features an extensive study of the current market landscape, market size and future opportunities for the antibody drug conjugate companies either developing the drugs or providing the necessary ADC technology, during the forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the antibody drug conjugate market are briefly discussed below.

Pipeline Analysis: Antibody Drug Conjugates Revolutionizing Cancer Treatment

Antibody drug conjugates landscape features the presence of over 140 very large, large, mid-sized and small drug developers. It is worth mentioning that, currently, more than 280 antibody drug conjugates are either approved or being evaluated in clinical trials, whereas 250 candidates are in preclinical stages of development. All the approved ADC therapeutics have been developed to target either solid tumor or hematological cancer. Majority of the pipeline antibody-drug conjugates are being developed for the treatment of cancer, particularly breast cancer.

ADC therapeutics offer a promising approach by targeting multiple disease pathways simultaneously. Kadcyla was the first HER2 ADC to be approved by FDA for the treatment of patients with breast cancer. Since then, two more ADC therapeutics, Daiichi Sankyo - AstraZeneca's Enhertu and Immunomedics' Trodelvy have received approval for the treatment of metastatic breast cancer as second-line treatment. Further, Daiichi Sankyo - AstraZeneca's Enhertu is expected to get EU approval for the treatment of non-small cell lung cancer in 2023. Presently, there are over 30 antibody drug conjugates that are under development for the treatment of breast cancer. According to the WHO statistics, breast cancer is the most prevalent cancer worldwide with an estimated 7.8 million women living with breast cancer at the end of 2020. In the same year, 2.3 million new cases of women diagnosed with breast cancer were reported.

In addition to breast cancer, the approved ADCs target indications, such as leukemia, lymphoma, urothelial cancer, multiple myeloma, cervical cancer, and ovarian cancer. The increasing prevalence of oncological disorders and a rich pipeline of ADC therapeutics targeting cancer is expected to drive the antibody drug conjugate market during the forecast period.

Market Analysis: Antibody Drug Conjugate Market Size

The global antibody drug conjugate market is estimated to be worth USD 7.72 billion in 2023. These represent the revenues generated by the sales of various ADC therapeutics. Driven by the growing demand for effective therapeutics for treatment of oncological disorders, along with growing developmental pipeline and encouraging clinical trial results, the antibody drug conjugates market is anticipated to grow at a CAGR of 9.63% during the forecast period.

Antibody drug conjugates have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional cancer treatment options) of antibody-drug conjugates. Therefore, the increasing prevalence of various oncological disorders is one of the key drivers for the antibody drug conjugate market.

Target Analysis: HER2 ADC will Hold a Significant ADC Market Share

Currently, more than 70 antibody drug conjugates are either approved or being evaluated in clinical trials targeting HER2 for the treatment of various oncological disorders, particularly breast cancer. Roche's Kadcyla was the first HER2 ADC to receive FDA approval in 2013, followed by Daiichi Sankyo / AstraZeneca's Enhertu in 2019. Another HER2 ADC, Aidixi, received conditional marketing approval from China's National Medical Products Administration for treatment of patients with locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) who have received at least two types of systemic chemotherapy. The drug has been developed by China based RemeGen Biosciences. Seagen acquired exclusive worldwide license, outside of Greater China, for development and commercialization of Aidixi from RemeGen. The antibody drug conjugate market for HER2 ADC is anticipated to grow at a CAGR of 8.16% during the forecast period.

Regional Analysis: North America to hold the Largest ADC Market Share in the Forecast Period

In the past few years, several well-funded start-ups / small companies, offering antibody drug conjugate having advanced linkers and more potent warheads have been established. Of these, majority of the companies are based in North America. Additionally, FDA has been actively reviewing and approving ADC therapeutics for cancer. The rising incidence of cancer in the US will drive the adoption of antibody drug conjugates. As per the American Cancer Society, over 1.9 million cancer patients were estimated to be diagnosed in the US in 2022.

The major risk factors for cancer include tobacco use, excess body weight, excess alcohol consumption, and infectious agents. All these factors will drive the market growth of the North American antibody drug conjugate market during the forecast period. In order to increase the adoption of antibody-drug conjugates among target population, ADC developers are offering several patient assistance / support programs which help the patient to deal with medical expenses. Examples of such programs include Ambrx patient assistance program, Bayer oncology patient assistance program and Genentech patient assistance program.

Technology Analysis: Advanced ADC Technology Supporting the Development of Next Generation ADCs

Antibody drug conjugates are a type of targeted cancer therapy that uses monoclonal antibodies to deliver a toxic payload to cancer cells. The most common cytotoxic payloads used in antibody drug conjugates are MMAE and DM4. The majority of ADCs use valine citrulline (VC) linkers or peptide linkers to attach the antibody to the toxic payload.

The development of novel ADC technologies, such as site-specific conjugation and novel linker technologies are expected to drive the antibody drug conjugate market growth in the coming years.

Clinical Trial Analysis: More than 550 Active Trials Testing ADC Monotherapy and Combination Therapy

Over the years, companies involved in the development of antibody drug conjugates (ADCs) have made significant efforts to evaluate the efficacy of antibody drug conjugates in clinical studies, for the treatment of various cancers. Currently, 150 antibody drug conjugates are being evaluated in more than 550 trials across different geographical regions. Majority of these trials (385) were registered in North America. Within this region, the maximum number of trials were / are being conducted in the US (379). Additionally, till February 2023, majority of the patients (39,226) were enrolled in trials conducted in North America, accounting for about 45% of the overall enrollment.

Market Trends Analysis: Partnership, Collaboration and Funding in Antibody Drug Conjugate Market

Currently, several partnerships have been inked by various industry and non-industry players engaged in the development of antibody-drug conjugates. It is worth highlighting that over 50 partnerships were inked in 2022 alone. Majority of such deals are focused on product and technology licensing. Further, in one of the largest acquisitions in the biopharmaceutical industry, Pfizer acquired Seagen in March 2023 for a total enterprise value of approximately USD 43 billion, with an aim to accelerate cancer breakthroughs in this market. This deal intends to bring new solutions to patients by combining Seagen's ADC technology with Pfizer's global reach. In addition to this, monetary assistance from angel investors, venture capitalists, and funding schemes of various public and private organizations / funds, along with assistance from regulatory authorities, have allowed start-ups / small companies to progress their R&D efforts related to the development of novel ADC therapeutics.

Leading Antibody Drug Conjugate Companies

Examples of the key antibody drug conjugate companies (the complete list of players is available in the full report) include ADC Therapeutics, Astellas Pharma, AstraZeneca, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, Pfizer, RemeGen. This market report includes an easily searchable excel database of all the antibody drug conjugate companies worldwide.

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research, offering a high-level view on the current state of the antibody drug conjugate market and its likely evolution in the mid-to-long term.
  • A brief introduction to antibody drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of these antibody-drug conjugates.
  • A detailed assessment of the market landscape of close to 400 antibody drug conjugates / ADC therapeutics that are either approved or being evaluated in different stages of development (clinical or pre-clinical), based on several relevant parameters, such as status of development (Approved, Phase III, Phase II, Phase I and Discovery / Preclinical), target disease indication (breast cancer, lung cancer, gastric cancer, ovarian cancer, non-Hodgkin's lymphoma, hepatic cancer, b-cell lymphoma, acute myeloid leukemia, brain cancer and renal cancer), therapeutic area (solid tumors, hematological cancers, autoimmune disorders / inflammatory disorders and others), line of treatment (1st line, ≥1st line, 2nd line, ≥2nd line, 3rd line, ≥3rd line, ≤4th line, Last line and others), dosing frequency (q3 weeks, q2 weeks, q1 weeks, q4 weeks, once and q6 weeks), type of therapy (combination therapy and monotherapy), target antigen (HER-2 (ERBB2), Trop-2, EGFR, FOLR1 (folate receptor alpha), CD30, B7-H3 (CD276), Nectin 4 and c-MET), antibody isotype (IgG1, IgG2 and IgG4), payload / cytotoxin / warhead (monomethyl auristatin E (MMAE), DM4, DM1, SG3199, SN-38 / irinotecan, duocarmycin and monomethyl auristatin F (MMAF)), type of payload (auristatin, Maytansinoid, camptothecin, exatecan derivative topoisomerase I inhibitor, pyrrolobenzodiazepine dimer, topoisomerase I inhibitor (unspecified), DNA topoisomerase I inhibitor, Seco-DUBA, calicheamicin (ozogamicin), glucocorticoid and pyrrolobenzodiazepine (PBD)), linkers (valine-citrulline, peptide linker, tetrapeptide-based linker, N-succinimidyl 4-(2-pyridyldithio) -butanoate (SPDB), valine-alanine, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate and maleimide linker) and type of linkers (cleavable and non-cleavable). In addition, the chapter features information on various antibody drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • An insightful competitiveness analysis of biological targets, featuring a (A) three-dimensional bubble representation that highlights the targets that are being evaluated for antibody drug conjugates development, taking into consideration number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody-drug conjugates for the target, and (B) a six-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including number of publications, number of grants received to support research on a particular target, number of companies involved in drug development based on a singular target, highest phase of development for the singular target, number of therapies and number of indications.
  • Elaborate profiles of leading antibody drug conjugate companies (shortlisted based on sales revenue of 2022) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • Elaborate profiles of marketed ADC therapeutics; each profile features an overview of the therapy, its mechanism of action, target antigen, linker, payload, type of therapy and details related to sales generated (wherever available).
  • An in-depth analysis of completed, ongoing, and planned clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry players, and non-industry players (in terms of number of trials) and key geographical regions.
  • An insightful analysis, highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibody drug conjugates, based on several relevant parameters, such as type of KOL, qualification(s), type of organization, affiliated organization, geographical location of KOLs and target disease indications. In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
  • An assessment of various therapeutics that are being evaluated in combination with antibody-drug conjugates. The study also presents the likely evolution of these therapeutics across different indications.
  • A detailed analysis of partnerships established by stakeholders engaged in this industry, since 2014, based on several relevant parameters, such as year of partnership, type of partnership (product licensing agreements, technology licensing agreements, research and development agreements, clinical trial agreements, mergers / acquisitions, product development agreements, technology utilization agreements, product development and commercialization agreements, manufacturing agreements, technology integration agreements and others), purpose of partnership (research and development, product development and commercialization, product development, clinical evaluation, portfolio enhancement, product development and manufacturing, manufacturing, research and others) type of partner, most active players (in terms of number of partnerships)., and regional distribution of partnership activity in the market.
  • An analysis of the various funding and investments made in the ADC domain, since 2014, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings based on several parameters, such as number of funding instances, amount invested, type of funding, leading companies and investors, and geographical analysis.
  • An in-depth analysis of the various patents that have been filed / granted related to antibody drug conjugates. It includes information on key parameters, such as type of patent, patent publication year, patent application year, geographical location, type of players, assigned CPC symbol, type of organization, and leading industry / academic players (in terms of size of intellectual property portfolio). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • A study of the various grants that have been awarded to research institutes engaged in conducting research related to antibody drug conjugates, since 2016, based on various important parameters, such as year of grant award, amount awarded, funding institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, popular NIH departments (based on number of grants awarded), prominent program officers, leading recipient organizations and key regions
  • An elaborate discussion on commercialization strategies adopted by various drug developers for their respective products, prior to product launch, during / post launch, featuring a proprietary framework, highlighting the necessary steps and guidelines that the companies endorse while developing a marketing strategy.
  • An analysis of the key promotional strategies that have been adopted by the developers of marketed products, namely Adcetris, Besponsa, Enhertu, Kadcyla, Mylotarg, Polivy, and Trodelvy.
  • An insightful success protocol analysis of recently approved ADC therapeutics, based on several relevant parameters, such as dosing frequency, drug efficacy, drug exclusivity, fatality rate, geographical reach, intra-class competition, line of treatment, prevalence, price, type of therapy, and existing competition among developers.
  • An overview on of various conjugation and linker technologies along with their types that are presently being employed in the designing and development of antibody drug conjugates; in addition, it presents a list of the conjugation and linker technologies that are presently being employed in the designing and development of antibody drug conjugates.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in antibody drug conjugates. The chapter presents findings from various antibody drug conjugate studies in different animal models. It also includes an analysis of different methods used in estimating FIH doses. In addition, it highlights the possible FIH starting doses and estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • An elaborate discussion on various factors that form the basis for the pricing of antibody drug conjugate products, featuring different models / approaches that pharmaceutical companies may choose to adopt while deciding the price of their respective lead therapy candidates that are likely to be marketed in the coming years.
  • A case study on manufacturing of antibody drug conjugates, highlighting the key challenges, and a list of contract service providers that are involved in the ADC market.
  • A case study on companies offering companion diagnostics that can potentially be used to make treatment related decisions involving antibody-drug conjugates, providing information on the geographical location of key diagnostic developers, affiliated disease biomarkers, assay techniques involved, target indications, the type of sample required (tumor tissue, blood, bone marrow and others) and the drug candidates for which a particular test was developed.
  • A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework, which are likely to impact the industry's evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

One of the key objectives of this market report was to estimate the current market size and the future growth potential of antibody drug conjugates over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the ADC market over the forecast period 2023-2035. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as target disease indication (breast cancer, B-cell lymphoma, lung cancer, multiple myeloma, acute lymphoblastic leukemia, gastric cancer, renal cancer, cervical cancer and other target disease indications), therapeutic area (hematological cancer and solid tumors), linker (valine-citrulline, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate, tetrapeptide-based linker, maleimide, maleimidocaproyl, valine-alanine, hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) and other linkers), payload (monomethyl auristatin E, DM1, duocarmycin, SN-38 / irinotecan, monomethyl auristatin F, SG3199, ozogamicin, DM4 and other payloads), target antigens (HER-2 (ERBB2), CD79b, TROP-2, BCMA (TNFRSF17 / BCM), CD19, CD22, tissue factor, CD30, CEACAM5, nectin 4 and others) and key geographical regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice, and other associations) to solicit their opinions on emerging trends in the market. This information is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What are ADCs / antibody drug conjugates?

Answer: Antibody drug conjugates are a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the small molecule (cytotoxic) drugs. Antibody drug conjugates are designed to selectively deliver a potent cytotoxic drug to cancer cells and minimize the toxic side effects associated with traditional chemotherapy.

Question 2: How many antibody drug conjugates are available in the market?

Answer: Currently 14 antibody-drug conjugates have been approved by various regulatory organizations for therapeutic use, across the globe, namely Kadcyla, Adcetris, Besponsa, Mylotarg, Polivy, Padcev, Trodelvy, Enhertu, Blenrep, Elahere, Tivdak, Akalux, Aidixi and Zynlonta.

Question 3: What is the mechanism of action of antibody drug conjugates?

Answer: Antibody drug conjugates (ADCs) are a class of cancer drugs that combine the targeting specificity of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. ADCs bind to their target antigens such as HER-2 (ERBB2), Trop-2, EGFR on the surface of cancer cells and are internalized through receptor-mediated endocytosis. This process releases the cytotoxic drug from the antibody drug conjugates, which kills the cancer cell with high specificity and minimizes toxicity to healthy cells.

Question 4: What are the most common antigens targeted by antibody drug conjugates?

Answer: HER-2 (ERBB2), Trop-2, EGFR, FOLR1 (Folate receptor alpha) and CD30, emerged as the most popular antigens targeted by various antibody drug conjugates.

Question 5: How many companies are developing antibody drug conjugates?

Answer: Close to 140 players are currently engaged in the evaluation and development of over 300 antibody drug conjugates in various stages of development.

Question 6: Which are the key companies in the antibody drug conjugate market?

Answer: Some of the key companies in the antibody drug conjugates market include ADC Therapeutics, Astellas Pharma, AstraZeneca, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, Pfizer and RemeGen.

Question 7: What is the partnership and collaboration trend in the antibody drug conjugates industry?

Answer: Currently, product licensing agreements, technology licensing agreements, research and development agreements and clinical trial agreements are the common types of partnerships inked by developers that are currently focused on the development of antibody drug conjugates.

Question 8: How big is the ADC market?

Answer: The global antibody drug conjugate market is estimated to be worth USD 7.72 billion in 2023.

Question 9: What is the top selling antibody-drug conjugate?

Answer: Kadcyla is the top selling antibody-drug conjugate with sales revenues of around USD 2.2 billion in the year 2022.

Question 10: What is the growth rate of antibody drug conjugate market?

Answer: The antibody drug conjugate market is expected to grow at a CAGR of ~10% during the forecast period.

Question 11: Which region has the highest growth rate in the antibody drug conjugates market?

Answer: Asia-pacific is likely to grow at the highest CAGR, over the period 2023-2035.

CHAPTER OUTLINES

  • Chapter 1: is a preface providing an overview of the full report, Antibody Drug Conjugates Market, 2023-2035.
  • Chapter 2: is an executive summary of the key insights captured during our research, offering a high-level view on the current state of the antibody drug conjugates market and its likely evolution in the short to mid and long term.
  • Chapter 3: provides a general overview of antibody drug conjugates, highlighting their historical background, as well as information on their structure, advantages, and the pharmacokinetic properties of antibody drug conjugates.
  • Chapter 4: provides information on more than 500 antibody drug conjugates that are either approved or under development for the treatment of various indications. It features a detailed analysis of marketed / under development molecules, based on status of development (Approved, Phase III, Phase II, Phase I and Discovery / Preclinical), target disease indication (breast cancer, lung cancer, gastric cancer, ovarian cancer, non-Hodgkin's lymphoma, hepatic cancer, b-cell lymphoma, acute myeloid leukemia, brain cancer and renal cancer), therapeutic area (solid tumors, hematological cancer, autoimmune disorder / inflammatory disease and others), line of treatment (1st line, ≥1st line, 2nd line, ≥2nd line, 3rd line, ≥3rd line, ≤4th line, Last line and others), dosing frequency (q3 weeks, q2 weeks, q1 weeks, q4 weeks, once and q6 weeks), type of therapy (combination therapy and monotherapy), target antigen (HER-2 (ERBB2), Trop-2, EGFR, FOLR1 (folate receptor alpha), CD30, B7-H3 (CD276), Nectin 4 and c-MET), antibody isotype (IgG1, IgG2 and IgG4), payload / cytotoxin / warhead (monomethyl auristatin E (MMAE), DM4, DM1, SG3199, SN-38 / irinotecan, duocarmycin and monomethyl auristatin F (MMAF)), type of payload (auristatin, Maytansinoid, camptothecin, exatecan derivative topoisomerase I inhibitor, pyrrolobenzodiazepine dimer, topoisomerase I inhibitor (unspecified), DNA topoisomerase I inhibitor, Seco-DUBA, calicheamicin (ozogamicin), glucocorticoid and pyrrolobenzodiazepine (PBD)), linkers (valine-citrulline, peptide linker, tetrapeptide-based linker, N-succinimidyl 4-(2-pyridyldithio) -butanoate (SPDB), valine-alanine, succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate and maleimide linker) and type of linkers (cleavable and non-cleavable). In addition, the chapter features information on various antibody drug conjugate developers, based on their year of establishment, company size, location of headquarters and most active players (in terms of number of therapies).
  • Chapter 5: featuring a (A) three-dimensional bubble representation that highlights the targets that are being evaluated for antibody drug conjugates development, taking into consideration number of antibody drug conjugates being developed against them, number of unique target disease indications and number of companies developing antibody drug conjugates for the target., and (B) a six-dimensional spider-web analysis, highlighting the most popular biological targets based on a number of relevant parameters, including number of publications, number of grants received to support research on a particular target, number of companies involved in drug development efforts based on a singular target, highest phase of development for the singular target, number of therapies and number of indications.
  • Chapter 6: presents elaborate profiles of companies (shortlisted based on sales revenue of 2022) and their respective product portfolios. Each profile features a brief overview of the company, its financial information (if available), product portfolio, recent developments, and an informed future outlook.
  • Chapter 7: presents an in-depth analysis of completed, ongoing, and planned clinical studies of various antibody drug conjugates, based on several relevant parameters, such as trial registration year, trial status, trial phase, enrolled patient population, type of sponsor / collaborator, target population, study design, most active industry, and non-industry players (in terms of number of trials) and key geographical regions.
  • Chapter 8: provides an analysis of KOLs in the field of antibody drug conjugates. The chapter highlighting the key opinion leaders (KOLs) investigating clinical trials related to antibody drug conjugates, based on several relevant parameters, such as type of KOL, qualification, type of organization, affiliated organization, geographical location of KOLs and target disease indication(s). In addition, the chapter highlights the most prominent KOLs, based on our proprietary and third-party scoring criteria.
  • Chapter 9: features an overview of the various therapeutics being evaluated in combination with antibody drug conjugates. It also features a study of the likely evolution of these therapeutics ac

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Antibody Drug Conjugate Market Overview
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Pillars of Cancer Therapy
  • 3.3. Overview of Antibody Drug Conjugates
    • 3.3.1. History of Antibody Drug Conjugates
    • 3.3.2. Difference between Small Molecule Drugs, Monoclonal Antibody Therapies and Antibody Drug Conjugates
    • 3.3.3. Components of Antibody Drug Conjugates
      • 3.3.3.1. Antibody
      • 3.3.3.2. Cytotoxin
      • 3.3.3.3. Linker
    • 3.3.4. Advantages of Antibody Drug Conjugates Therapeutics over Traditional Therapeutics
    • 3.3.5. Pharmacokinetic Properties of Antibody-Drug Conjugates
      • 3.3.5.1. Absorption
      • 3.3.5.2. Distribution
      • 3.3.5.3. Metabolism and Elimination
  • 3.4. Concluding Remarks

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Antibody Drug Conjugates: Therapies Pipeline
    • 4.2.1. Analysis by Status of Development
    • 4.2.2. Analysis by Target Disease Indication
    • 4.2.3. Analysis by Therapeutic Area
    • 4.2.4. Analysis by Line of Treatment
    • 4.2.5. Analysis by Dosing Frequency
    • 4.2.6. Analysis by Type of Therapy
    • 4.2.7. Analysis by Target Antigen
    • 4.2.8. Analysis by Antibody Isotype
    • 4.2.9. Analysis by Payload / Cytotoxin / Warhead
    • 4.2.10. Analysis by Type of Payload
    • 4.2.11. Analysis by Linker
    • 4.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
  • 4.3. Antibody Drug Conjugate: List of Therapy Developers
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Company size and Location of Headquarters
    • 4.3.5. Most Active Players: Analysis by Number of Therapies

5. TARGET COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Key Parameters
  • 5.3. Methodology
  • 5.4. Target Competitiveness Analysis: Key Targets of Antibody Drug Conjugates
    • 5.4.1. Three-Dimensional Bubble Analysis
      • 5.4.1.1. Targets of Approved / Marketed Drugs
      • 5.4.1.2. Targets of Phase III Drugs
      • 5.4.1.3. Targets of Phase II Drugs
      • 5.4.1.4. Targets of Phase I Drugs
      • 5.4.1.5. Targets of Pre-Clinical Drugs
    • 5.4.2. Six-Dimensional Spider Web Analysis

6. COMPANY AND DRUG PROFILES

  • 6.1. Chapter Overview
  • 6.2. ADC Therapeutics
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Pipeline Overview
      • 6.2.3.1. Zynlonta
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Astellas Pharma
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Pipeline Overview
      • 6.3.3.1. Padcev
    • 6.3.4. Recent Developments and Future Outlook
  • 6.4. AstraZeneca
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Pipeline Overview
      • 6.4.3.1. Enhertu
    • 6.4.4. Recent Developments and Future Outlook
  • 6.5. Byondis
    • 6.5.1. Company Overview
    • 6.5.2. Financial Information
      • 6.5.2.1. Pipeline Overview
    • 6.5.3. Trastuzumab duocarmazine
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. Daiichi Sankyo
    • 6.6.1. Company Overview
    • 6.6.2. Financial Information
    • 6.6.3. Pipeline Overview
      • 6.6.3.1. Enhertu
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Genentech (Subsidiary of Roche)
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Pipeline Overview
      • 6.7.3.1. Kadcyla
      • 6.7.3.2. Polivy
    • 6.7.4. Recent Developments and Future Outlook
  • 6.8. Gilead Sciences
    • 6.8.1. Company Overview
    • 6.8.2. Financial Information
    • 6.8.3. Pipeline Overview
      • 6.8.3.1. Trodelvy
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. ImmunoGen
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Pipeline Overview
      • 6.9.3.1. Elahere
    • 6.9.4. Recent Developments and Future Outlook
  • 6.10. Pfizer
    • 6.10.1. Company Overview
    • 6.10.2. Financial Information
    • 6.10.3. Pipeline Overview
      • 6.10.3.1. Mylotarg
      • 6.10.3.2. Besponsa
    • 6.10.4. Recent Developments and Future Outlook
  • 6.11. RemeGen
    • 6.11.1. Company Overview
    • 6.11.2. Financial Information
    • 6.11.3. Pipeline Overview
      • 6.11.3.1. Disitamab vedotin
    • 6.11.4. Recent Developments and Future Outlook
  • 6.12. Seagen
    • 6.12.1. Company Overview
    • 6.12.2. Financial Information
    • 6.12.3. Pipeline Overview
      • 6.12.3.1. Adcetris
      • 6.12.3.2. Padcev
      • 6.12.3.3. Tivdak
    • 6.12.4. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Antibody Drug Conjugates: Clinical Trial Analysis
    • 7.3.1. Analysis by Trial Registration Year
    • 7.3.2. Analysis by Trial Status
    • 7.3.3. Analysis by Trial Status and Patients Enrolled
    • 7.3.4. Analysis by Trial Registration Year and Trial Status
    • 7.3.5. Analysis by Trial Registration Year and Patients Enrolled
    • 7.3.6. Analysis by Trial Phase
    • 7.3.7. Analysis by Trial Phase and Patients Enrolled
    • 7.3.8. Analysis by Type of Sponsor / Collaborator
    • 7.3.9. Analysis by Target Population
    • 7.3.10. Analysis by Study Design
    • 7.3.11. Most Active Industry Players: Analysis by Number of Trials
    • 7.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
    • 7.3.13. Analysis of Clinical Trials by Geography
    • 7.3.14. Analysis of Patients Enrolled by Geography

8. KEY OPINION LEADERS

  • 8.1. Chapter Overview
  • 8.2. Assumption and Key Parameters
  • 8.3. Methodology
  • 8.4. Antibody Drug Conjugates: Key Opinion Leaders
    • 8.4.1. Analysis by Type of KOLs
    • 8.4.2. Analysis by Qualification
    • 8.4.3. Analysis by Affiliated Organization
    • 8.4.4. Analysis by Type of Organization
    • 8.4.5. Analysis by Geographical Location of KOLs
    • 8.4.6. Most Prominent KOLs: Analysis by KOLs Activeness, Expertise and Strength
    • 8.4.7. Most Prominent KOLs: Analysis by RA score
    • 8.4.8. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9. COMBINATION THERAPIES

  • 9.1. Chapter Overview
  • 9.2. Combination Therapies: History of Development
  • 9.3. Combination Therapies: FDA Guidelines
    • 9.3.1. Combination of Marketed Drugs
    • 9.3.2. Combinations of Marketed Drugs with New Molecular Entities
    • 9.3.3. Combination of New Molecular Entities
  • 9.4. Combination Therapies: Antibody Drug Conjugates
    • 9.4.1. Completed / Ongoing Clinical Studies of Antibody Drug Conjugates
      • 9.4.1.1. Analysis by Type of Therapy
    • 9.4.2. Completed / Ongoing Clinical Studies of Antibody Drug Conjugate-based Combination Therapies
      • 9.4.2.1. Analysis by Phase of Development
      • 9.4.2.2. Analysis by Trial Status
      • 9.4.2.3. Analysis by Target Disease Indication
      • 9.4.2.4. Most Popular Antibody Drug Conjugates Used in Combination Therapies: Analysis by Number of Trials
      • 9.4.2.5. Most Popular Drug Class Used in Combination Therapies: Analysis by Number of Trials
      • 9.4.2.6. Analysis by Target Disease Indication and Drug Class Used in Antibody Drug Conjugate-based Combination Therapies

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Antibody Drug Conjugates: List of Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Purpose of Partnership
    • 10.3.5. Analysis by Type of Partner
    • 10.3.6. Most Active Players: Analysis by Number of Partnerships
    • 10.3.7. Analysis by Geography
      • 10.3.7.1. International and Local Agreements
      • 10.3.7.2. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Types of Funding
  • 11.3. Antibody Drug Conjugates: List of Funding and Investment Analysis
    • 11.3.1. Analysis by Year of Funding
    • 11.3.2. Analysis by Amount Invested
    • 11.3.3. Analysis by Type of Funding
    • 11.3.4. Analysis by Year and Type of Funding
    • 11.3.5. Analysis by Type of Investor
    • 11.3.6. Analysis by Amount Invested by Geography
      • 11.3.6.1. Analysis by Region
      • 11.3.6.2. Analysis by Country
    • 11.3.7. Most Active Players: Analysis by Number of Funding Instances
    • 11.3.8. Most Active Players: Analysis by Amount Invested
    • 11.3.9. Key Investors: Analysis by Number of Funding Instances

12. PATENT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Scope and Methodology
  • 12.3. Antibody Drug Conjugates: Patent Analysis
    • 12.3.1. Analysis by Patent Publication Year
    • 12.3.2. Analysis by Patent Application Year
    • 12.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
    • 12.3.4. Analysis by Patent Jurisdiction
    • 12.3.5. Analysis by CPC Symbols
    • 12.3.6. Analysis by Type of Applicant
    • 12.3.7. Leading Industry Players: Analysis by Number of Patents
    • 12.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 12.3.9. Leading Individual Assignees: Analysis by Number of Patents
  • 12.4. Antibody Drug Conjugate: Patent Benchmarking Analysis
    • 12.4.1. Analysis by Patent Characteristics
  • 12.5. Antibody Drug Conjugate: Patent Valuation
  • 12.6. Leading Patents by Number of Citations

13. ACADEMIC GRANTS ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. Antibody Drug Conjugates: Grants Analysis
    • 13.3.1. Analysis by Year of Grant Award
    • 13.3.2. Analysis by Amount Awarded
    • 13.3.3. Analysis by Funding Institute
    • 13.3.4. Analysis by Support Period
    • 13.3.5. Analysis by Type of Grant Application
    • 13.3.6. Analysis by Purpose of Grant Award
    • 13.3.7. Analysis by Activity Code
    • 13.3.8. Analysis by Study Section Involved
    • 13.3.9. Popular NIH Departments: Analysis by Number of Grants
      • 13.3.9.1. Prominent Program Officers: Analysis by Number of Grants
      • 13.3.9.2. Popular Recipient Organizations: Analysis by Number of Grants
      • 13.3.9.3. Popular Recipient Organizations: Analysis by Grant Amount
    • 13.3.10. Analysis by Region of Recipient Organization

14. KEY COMMMERCIALIZATION STRATEGIES

  • 14.1. Chapter Overview
  • 14.2. Successful Drug Launch Strategy: ROOTS Framework
  • 14.3. Successful Drug Launch Strategy: Product Differentiation
  • 14.4. Common Commercialization Strategies Adopted Across Different Stages of Product Development
  • 14.5. Key Commercialization Strategies Adopted by the Companies Focused on Antibody Drug Conjugates
    • 14.5.1. Participation in the Global Events
    • 14.5.2. Collaboration with External Stakeholders and Pharmaceuticals Firms
    • 14.5.3. Geographical Expansion
    • 14.5.4. Awareness Through Product Website
  • 14.6. Concluding Remarks

15. PROMOTIONAL ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Channels Used for Promotional Campaigns
  • 15.3. Summary of Product Website
  • 15.4. Summary of Patient Support Services and Informative Downloads
  • 15.5. Adcetris: Promotional Analysis
    • 15.5.1. Drug Overview
    • 15.5.2. Product Website Analysis
      • 15.5.2.1. Message for Healthcare Professional
      • 15.5.2.2. Message for Patients
      • 15.5.2.3. Informative Downloads
      • 15.5.2.4. Patient Support Services
  • 15.6. Besponsa: Promotional Analysis
    • 15.6.1. Drug Overview
    • 15.6.2. Product Website Analysis
      • 15.6.2.1. Message for Healthcare Professional
      • 15.6.2.2. Message for Patients
      • 15.6.2.3. Informative Downloads
      • 15.6.2.4. Patient Support Services
  • 15.7. Enhertu: Promotional Analysis
    • 15.7.1. Drug Overview
    • 15.7.2. Product Website Analysis
      • 15.7.2.1. Message for Healthcare Professional
      • 15.7.2.2. Message for Patients
      • 15.7.2.3. Informative Downloads
      • 15.7.2.4. Patient Support Services
  • 15.8. Kadcyla: Promotional Analysis
    • 15.8.1. Drug Overview
    • 15.8.2. Product Website Analysis
      • 15.8.2.1. Message for Healthcare Professional
      • 15.8.2.2. Message for patients
      • 15.8.2.3. Informative Downloads
      • 15.8.2.4. Patient Support Services
  • 15.9. Mylotarg: Promotional Analysis
    • 15.9.1. Drug Overview
    • 15.9.2. Product Website Analysis
      • 15.9.2.1. Message for Healthcare Professional
      • 15.9.2.2. Message for patients
      • 15.9.2.3. Informative Downloads
      • 15.9.2.4. Patient Support Services
  • 15.10. Polivy: Promotional Analysis
    • 15.10.1. Drug Overview
    • 15.10.2. Product Website Analysis
      • 15.10.2.1. Message for Healthcare Professional
      • 15.10.2.2. Message for Patients
      • 15.10.2.3. Informative Downloads
      • 15.10.2.4. Patient Support Services
  • 15.11. Trodelvy: Promotional Analysis
    • 15.11.1. Drug Overview
    • 15.11.2. Product Website Analysis
      • 15.11.2.1. Message for Healthcare Professional
      • 15.11.2.2. Message for Patients
      • 15.11.2.3. Informative Downloads
      • 15.11.2.4. Patient Support Services

16. SUCCESS PROTOCOL ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Antibody Drug Conjugates: Success Protocol Analysis
  • 16.3. Adcetris (Seagen / Takeda Oncology)
    • 16.3.1. Overview
    • 16.3.2. Approval Timeline
    • 16.3.3. Success Protocol Analysis
  • 16.4. Aidixi (RemeGen)
    • 16.4.1. Overview
    • 16.4.2. Approval Timeline
    • 16.4.3. Success Protocol Analysis
  • 16.5. Akalux (Rakuten Medical)
    • 16.5.1. Overview
    • 16.5.2. Approval Timeline
    • 16.5.3. Success Protocol Analysis
  • 16.6. Besponsa (Pfizer / UCB)
    • 16.6.1. Overview
    • 16.6.2. Approval Timeline
    • 16.6.3. Success Protocol Analysis
  • 16.7. Blenrep (GlaxoSmithKline)
    • 16.7.1. Overview
    • 16.7.2. Approval Timeline
    • 16.7.3. Success Protocol Analysis
  • 16.8. Elahere (ImmunoGen)
    • 16.8.1. Overview
    • 16.8.2. Approval Timeline
    • 16.8.3. Success Protocol Analysis
  • 16.9. Enhertu (Daiichi Sankyo / AstraZeneca)
    • 16.9.1. Overview
    • 16.9.2. Approval Timeline
    • 16.9.3. Success Protocol Analysis
  • 16.10. Kadcyla (Genentech / ImmunoGen)
    • 16.10.1. Overview
    • 16.10.2. Approval Timeline
    • 16.10.3. Success Protocol Analysis
  • 16.11. Padcev (Seagen / Astellas Pharma)
    • 16.11.1. Overview
    • 16.11.2. Approval Timeline
    • 16.11.3. Success Protocol Analysis
  • 16.12. Polivy (Genentech)
    • 16.12.1. Overview
    • 16.12.2. Approval Timeline
    • 16.12.3. Success Protocol Analysis
  • 16.13. Tivdak (Seagen / Genmab)
    • 16.13.1. Overview
    • 16.13.2. Approval Timeline
    • 16.13.3. Success Protocol Analysis
  • 16.14. Trodelvy (Gilead Sciences)
    • 16.14.1. Overview
    • 16.14.2. Approval Timeline
    • 16.14.3. Success Protocol Analysis
  • 16.15. Zynlonta (ADC Therapeutics)
    • 16.15.1. Overview
    • 16.15.2. Approval Timeline
    • 16.15.3. Success Protocol Analysis
  • 16.16. Concluding Remarks

17. NOVEL CONJUGATION AND LINKER TECHNOLOGY PLATFORMS

  • 17.1. Chapter Overview
  • 17.2. Antibody Drug Conjugates: Conjugation Technologies
    • 17.2.1. Chemical Conjugation
    • 17.2.2. Enzymatic Conjugation
  • 17.3. Antibody Drug Conjugates: List of Conjugation Technologies
  • 17.4. Antibody Drug Conjugates: Linker Technologies
    • 17.4.1. Non-cleavable Linkers
    • 17.4.2. Cleavable Linker
  • 17.5. Antibody Drug Conjugates: List of Linker and Linker-Payload Technologies
  • 17.6. Concluding Remarks

18. ASSESSMENT OF NON-CLINICAL DATA FIRST IN HUMAN DOSING

  • 18.1. Chapter Overview
  • 18.2. Antibody Drug Conjugates: Non-Clinical Studies
  • 18.3. ICH S9 Guidelines
  • 18.4. Investigational New Drug (IND)-Enabling Study Designs
    • 18.4.1. Example Case: Kadcyla
  • 18.5. Toxicities in Animal Models
  • 18.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
  • 18.7. Other Key Considerations for Study Design

19. COST PRICE ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Factors Contributing Towards the High Price of Antibody-Drug Conjugates
  • 19.3. Antibody Drug Conjugates Market: Cost Price Analysis
    • 19.3.1. On the Basis of Associated Costs
    • 19.3.2. On the Basis of Competition
    • 19.3.3. On the Basis of Patient Segment
  • 19.4. Reimbursement Considerations for Antibody-Drug Conjugates

20. CASE STUDY 1: CONTRACT MANUFACTURING OF ANTIBODY-DRUG CONJUGATES

  • 20.1. Chapter Overview
  • 20.2. Key Steps in Antibody Drug Conjugate Manufacturing Process
  • 20.3. Technical Challenges Related to Antibody Drug Conjugate Manufacturing
  • 20.4. Challenges Associated with Supply Chain and Method Transfer
  • 20.5. Limitations of In-House Manufacturing
  • 20.6. Investments in Antibody Drug Conjugate Manufacturing Capability Expansions
  • 20.7. Collaborations Established for Antibody-Drug Conjugate Manufacturing
  • 20.8. Growing Demand for Antibody-Drug Conjugate Contract Manufacturing
  • 20.9. CMOs with Linker Manufacturing Capabilities
  • 20.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
  • 20.11. CMOs with Conjugation Capabilities
  • 20.12. Antibody Drug Conjugate One-Stop-Shops
  • 20.13. Increasing Demand for One-Stop-Shops

21. CASE STUDY 2: COMPANION DIAGNOSTICS FOR ANTIBODY DRUG CONJUGATES THERAPEUTICS

  • 21.1. Chapter Overview
    • 21.1.1. Advantages of Companion Diagnostics
    • 21.1.2. Challenges Associated with the Development of Companion Diagnostics
  • 21.2. Companion Diagnostics for Antibody Drug Conjugates
  • 21.3. Companion Diagnostics For Antibody Therapeutics
    • 21.3.1. Analysis by Target Antigen
    • 21.3.2. Analysis by Type of Cancer
  • 21.4. Most Prominent Players: Analysis by Number of Tests

22. SWOT ANALYSIS

  • 22.1. Chapter Overview
  • 22.2. Strengths
    • 22.2.1. Improved Safety and Patient Adherence
    • 22.2.2. Rise of Next-Generation Conjugation Technologies
    • 22.2.3. Robust Pipeline with Multiple Late Stage Product Candidates
    • 22.2.4. Growing Involvement of Academic Institutes
  • 22.3. Weaknesses
    • 22.3.1. Technical Complexities Associated with Product Development
    • 22.3.2. Manufacturing, Logistics and Supply Chain Challenges
    • 22.3.3. Batch to Batch Inconsistencies
  • 22.4. Opportunities
    • 22.4.1. Increasing Collaborations and VC Funding
    • 22.4.2. Widening Therapeutics Reach
    • 22.4.3. Life Cycle Management
    • 22.4.4. Combination Therapies
    • 22.4.5. Opportunities for CMOs
  • 22.5. Threats
    • 22.5.1. Failure of Clinical / Marketed Candidates
    • 22.5.2. Increased Competition from Other Therapeutic Classes

23. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 23.1. Chapter Overview
  • 23.2. Forecast Methodology and Key Assumptions
  • 23.3. Global Antibody Drug Conjugates Market, 2023-2035
    • 23.3.1. Global Antibody Drug Conjugates Market: Distribution by Target Disease Indication, 2023 and 2035
      • 23.3.1.1. Antibody Drug Conjugates Market for Breast Cancer, 2023-2035
      • 23.3.1.2. Antibody Drug Conjugates Market for B-cell Lymphoma, 2023-2035
      • 23.3.1.3. Antibody Drug Conjugates Market for Lung Cancer, 2023-2035
      • 23.3.1.4. Antibody Drug Conjugates Market for Multiple Myeloma, 2023-2035
      • 23.3.1.5. Antibody Drug Conjugates Market for Renal Cancer, 2023-2035
      • 23.3.1.6. Antibody Drug Conjugates Market for Gastric Cancer, 2023-2035
      • 23.3.1.7. Antibody Drug Conjugates Market for Cervical Cancer, 2023-2035
      • 23.3.1.8. Antibody Drug Conjugates Market for Acute Lymphoblastic Leukemia, 2023-2035
      • 23.3.1.9. Antibody Drug Conjugates Market for Other Disease Indications, 2023-2035
    • 23.3.2. Antibody Drug Conjugates Market: Distribution by Therapeutic Area, 2023 and 2035
      • 23.3.2.1. Antibody Drug Conjugates Market for Solid Tumors, 2023-2035
      • 23.3.2.2. Antibody Drug Conjugates Market for Hematological Cancer, 2023-2035
    • 23.3.3. Global Antibody Drug Conjugates Market: Distribution by Linker, 2023 and 2035
      • 23.3.3.1. Antibody Drug Conjugates Market for Valine-Citrulline Linker, 2023-2035
      • 23.3.3.2. Antibody Drug Conjugates Market for Tetrapeptide-Based Linker, 2023-2035
      • 23.3.3.3. Antibody Drug Conjugates Market for Succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate Linker, 2023-2035
      • 23.3.3.4. Antibody Drug Conjugates Market for Maleimide Linker, 2023-2035
      • 23.3.3.5. Antibody Drug Conjugates Market for Maleimidocaproyl Linker, 2023-2035
      • 23.3.3.6. Antibody Drug Conjugates Market for Valine-Alanine Linker, 2023-2035
      • 23.3.3.7. Antibody Drug Conjugates Market for Hydrazone (4-(4-acetylphenoxy) butanoic acid (AcBut) Linker, 2023-2035
      • 23.3.3.8. Antibody Drug Conjugates Market for Other Linkers, 2023-2035
    • 23.3.4. Antibody Drug Conjugates Market: Distribution by Type of Payload, 2023 and 2035
      • 23.3.4.1. Antibody Drug Conjugates Market for Monomethyl Auristatin E Payloads, 2023-2035
      • 23.3.4.2. Antibody Drug Conjugates Market for DM1 Payloads, 2023-2035
      • 23.3.4.3. Antibody Drug Conjugates Market for SN-38 / Irinotecan Payloads, 2023-2035
      • 23.3.4.4. Antibody Drug Conjugates Market for Monomethyl Auristatin F Payloads, 2023-2035
      • 23.3.4.5. Antibody Drug Conjugates Market for Duocarmycin Payloads, 2023-2035
      • 23.3.4.6. Antibody Drug Conjugates Market for SG3199 Payloads, 2023-2035
      • 23.3.4.7. Antibody Drug Conjugates Market for Ozogamicin Payloads, 2023-2035
      • 23.3.4.8. Antibody Drug Conjugates Market for DM4 Payloads, 2023-2035
      • 23.3.4.9. Antibody Drug Conjugates Market for Other Payloads, 2023-2035
    • 23.3.5. Global Antibody Drug Conjugates Market: Distribution by Target Antigen, 2023 and 2035
      • 23.3.5.1. Antibody Drug Conjugates Market for HER-2 (ERBB2), 2023-2035
      • 23.3.5.2. Antibody Drug Conjugates Market for CD79b, 2023-2035
      • 23.3.5.3. Antibody Drug Conjugates Market for TROP-2, 2023-2035
      • 23.3.5.4. Antibody Drug Conjugates Market for BCMA (TNFRSF17 / BCM), 2023-2035
      • 23.3.5.5. Antibody Drug Conjugates Market for CD19, 2023-2035
      • 23.3.5.6. Antibody Drug Conjugates Market for Nectin 4, 2023-2035
      • 23.3.5.7. Antibody Drug Conjugates Market for Tissue Factor, 2023-2035
      • 23.3.5.8. Antibody Drug Conjugates Market for CD22, 2023-2035
      • 23.3.5.9. Antibody Drug Conjugates Market for CD30, 2023-2035
      • 23.3.5.10. Antibody Drug Conjugates Market for CEACAM5, 2023-2035
      • 23.3.5.11. Antibody Drug Conjugates Market for Other Target Antigens, 2023-2035
    • 23.3.6. Antibody Drug Conjugates Market: Distribution by Geographical Regions, 2023 and 2035
      • 23.3.6.1. Antibody Drug Conjugates Market in North America, 2023-2035
        • 23.3.6.1.1. Antibody Drug Conjugates Market in US, 2023-2035
        • 23.3.6.1.2. Antibody Drug Conjugates Market in Canada, 2023-2035
      • 23.3.6.2. Antibody Drug Conjugates Market in Europe, 2023-2035
        • 23.3.6.2.1. Antibody Drug Conjugates Market in Germany, 2023-2035
        • 23.3.6.2.2. Antibody Drug Conjugates Market in UK, 2023-2035
        • 23.3.6.2.3. Antibody Drug Conjugates Market in France, 2023-2035
        • 23.3.6.2.4. Antibody Drug Conjugates Market in Italy, 2023-2035
        • 23.3.6.2.5. Antibody Drug Conjugates Market in Spain, 2023-2035
      • 23.3.6.3. Antibody Drug Conjugates Market in Asia-Pacific, 2023-2035
        • 23.3.6.3.1. Antibody Drug Conjugates Market in China, 2023-2035
        • 23.3.6.3.2. Antibody Drug Conjugates Market in Australia, 2023-2035
        • 23.3.6.3.3. Antibody Drug Conjugates Market in Japan, 2023-2035
  • 23.4. Antibody Drug Conjugates Market: Product-wise Sales Forecast, 2023-2035
    • 23.4.1. Adcetris
      • 23.4.1.1. Sales Forecast (USD Billion)
      • 23.4.1.2. Net Present Value (USD Billion)
      • 23.4.1.3. Value Creation Analysis
    • 23.4.2. Aidixi
      • 23.4.2.1. Sales Forecast (USD Billion)
      • 23.4.2.2. Net Present Value (USD Billion)
      • 23.4.2.3. Value Creation Analysis
    • 23.4.3. Besponsa
      • 23.4.3.1. Sales Forecast (USD Billion)
      • 23.4.3.2. Net Present Value (USD Billion)
      • 23.4.3.3. Value Creation Analysis
    • 23.4.4. Blenrep
      • 23.4.4.1. Sales Forecast (USD Billion)
      • 23.4.4.2. Net Present Value (USD Billion)
      • 23.4.4.3. Value Creation Analysis
    • 23.4.5. Elahere
      • 23.4.5.1. Sales Forecast (USD Billion)
      • 23.4.5.2. Net Present Value (USD Billion)
      • 23.4.5.3. Value Creation Analysis
    • 23.4.6. Enhertu
      • 23.4.6.1. Sales Forecast (USD Billion)
      • 23.4.6.2. Net Present Value (USD Billion)
      • 23.4.6.3. Value Creation Analysis
    • 23.4.7. Kadcyla
      • 23.4.7.1. Sales Forecast (USD Billion)
      • 23.4.7.2. Net Present Value (USD Billion)
      • 23.4.7.3. Value Creation Analysis
    • 23.4.8. Padcev
      • 23.4.8.1. Sales Forecast (USD Billion)
      • 23.4.8.2. Net Present Value (USD Billion)
      • 23.4.8.3. Value Creation Analysis
    • 23.4.9. Polivy
      • 23.4.9.1. Sales Forecast (USD Billion)
      • 23.4.9.2. Net Present Value (USD Billion)
      • 23.4.9.3. Value Creation Analysis
    • 23.4.10. Tivdak
      • 23.4.10.1. Sales Forecast (USD Billion)
      • 23.4.10.2. Net Present Value (USD Billion)
      • 23.4.10.3. Value Creation Analysis
    • 23.4.11. Trodelvy
      • 23.4.11.1. Sales Forecast (USD Billion)
      • 23.4.11.2. Net Present Value (USD Billion)
      • 23.4.11.3. Value Creation Analysis
    • 23.4.12. Zynlonta
      • 23.4.12.1. Sales Forecast (USD Billion)
      • 23.4.12.2. Net Present Value (USD Billion)
      • 23.4.12.3. Value Creation Analysis
    • 23.4.13. Datopotamab Deruxtecan
      • 23.4.13.1. Sales Forecast (USD Billion)
      • 23.4.13.2. Net Present Value (USD Billion)
      • 23.4.13.3. Value Creation Analysis
    • 23.4.14. Patritumab Deruxtecan
      • 23.4.14.1. Sales Forecast (USD Billion)
      • 23.4.14.2. Net Present Value (USD Billion)
      • 23.4.14.3. Value Creation Analysis
    • 23.4.15. SHR-A1811
      • 23.4.15.1. Sales Forecast (USD Billion)
      • 23.4.15.2. Net Present Value (USD Billion)
      • 23.4.15.3. Value Creation Analysis
    • 23.4.16. SKB264
      • 23.4.16.1. Sales Forecast (USD Billion)
      • 23.4.16.2. Net Present Value (USD Billion)
      • 23.4.16.3. Value Creation Analysis
    • 23.4.17. TAA013
      • 23.4.17.1. Sales Forecast (USD Billion)
      • 23.4.17.2. Net Present Value (USD Billion)
      • 23.4.17.3. Value Creation Analysis
    • 23.4.18. Telisotuzumab Vedotin
      • 23.4.18.1. Sales Forecast (USD Billion)
      • 23.4.18.2. Net Present Value (USD Billion)
      • 23.4.18.3. Value Creation Analysis
    • 23.4.19. Trastuzumab Duocarmazine
      • 23.4.19.1. Sales Forecast (USD Billion)
      • 23.4.19.2. Net Present Value (USD Billion)
      • 23.4.19.3. Value Creation Analysis
    • 23.4.20. Tusamitamab Ravtansine
      • 23.4.20.1. Sales Forecast (USD Billion)
      • 23.4.20.2. Net Present Value (USD Billion)
      • 23.4.20.3. Value Creation Analysis
    • 23.4.21. Upifitamab Rilsodotin
      • 23.4.21.1. Sales Forecast (USD Billion)
      • 23.4.21.2. Net Present Value (USD Billion)
      • 23.4.21.3. Value Creation Analysis

24. EXECUTIVE INSIGHTS

  • 24.1. Chapter Overview
  • 24.2. Oxford Biotherapeutics
    • 24.2.1. Company Snapshot
    • 24.2.2. Interview Transcript: Christian Rohlff, Founder and Chief Executive Officer
  • 24.3. Angiex
    • 24.3.1. Company Snapshot
    • 24.3.2. Interview Transcript: Paul Jaminet, Founder and Chief Operating Officer
  • 24.4. Syndivia
    • 24.4.1. Company Snapshot
    • 24.4.2. Interview Transcript: Sasha Koniev, Co-Founder and Chief Executive Officer
  • 24.5. BSP Pharmaceuticals
    • 24.5.1. Company Snapshot
    • 24.5.2. Interview Transcript: Aldo Braca, President and Chief Executive Officer and Giorgio Salciarini, Technical Business Development Senior Manager
  • 24.6. PolyTherics (an Abzena company)
    • 24.6.1. Company Snapshot
    • 24.6.2. Interview Transcript: John Burt, Former Chief Executive Officer
  • 24.7. CureMeta
    • 24.7.1. Company Snapshot
    • 24.7.2. Interview Transcript: Michael Schopperle, Founder and Chief Executive Officer
  • 24.8. CytomX Therapeutics
    • 24.8.1. Company Snapshot
    • 24.8.2. Interview Transcript: Jeff Landau, Chief Business Officer and Head of Strategy
  • 24.9. NBE-Therapeutics
    • 24.9.1. Company Snapshot
    • 24.9.2. Interview Transcript: Wouter Verhoeven, Former Chief Business Officer
  • 24.10. Cerbios-Pharma
    • 24.10.1. Company Snapshot
    • 24.10.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer
  • 24.11. Eisai
    • 24.11.1. Company Snapshot
    • 24.11.2. Interview Transcript: Toshimitsu Uenaka, President and Takashi Owa, Senior Vice President and Chief Scientific Officer
  • 24.12. AbTis
    • 24.12.1. Company Snapshot
    • 24.12.2. Interview Transcript: Justin Oh, Chief Business Officer
  • 24.13. AmbrX
    • 24.13.1. Company Snapshot
    • 24.13.2. Interview Transcript: Sukumar Sakamuri, Former Vice President and Head of Chemistry
  • 24.14. Synaffix
    • 24.14.1. Company Snapshot
    • 24.14.2. Interview Transcript: Anthony DeBoer, Vice President, Business Development
  • 24.15. Pierre Fabre
    • 24.15.1. Company Snapshot
    • 24.15.2. Interview Transcript: Christian Bailly, Former Director
  • 24.16. Catalent Pharma Solutions
    • 24.16.1. Company Snapshot
    • 24.16.2. Interview Transcript: Jennifer L. Mitcham, Former Director, SMARTag ADCs and Bioconjugates and Stacy McDonald, Former Group Product Manager
  • 24.17. Lonza
    • 24.17.1. Company Snapshot
    • 24.17.2. Interview Transcript: Laurent Ducry, Former Head of Bioconjugates Commercial Development
  • 24.18. Piramal Healthcare
    • 24.18.1. Company Snapshot
    • 24.18.2. Interview Transcript: Mark Wright, Former Site Head
  • 24.19. Ajinomoto Bio-Pharma Services
    • 24.19.1. Company Snapshot
    • 24.19.2. Interview Transcript: Tatsuya Okuzumi, General Manager, Business Development, CDMO Business
  • 24.20. Cardiff University
    • 24.20.1. Company Snapshot
    • 24.20.2. Interview Transcript: Alan Burnett, Professor, School of Medicine
  • 24.21. Anonymous, Director, Business Development, Leading CMO
  • 24.22. Anonymous, Chief Executive Officer, Leading CMO

25. CONCLUSION

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS